Jamshidi-Parsian A, Jenkins SV, Tran A, Bragg A, Davis R, Griffin C, Siegel E, Dings RPM, Griffin RJ, Boysen G. CB-839 induces reversible dormancy in lung tumor-cells. Eur J Pharmacol. 2024 Nov 05; 982:176912.

Buck C, Brenes Castillo F, Bettio E, Land J, McCourt O, Poole H, Tarling R, Yong K, Popat R, Lee L, McMillan A, Papanikolaou X, Xu K, Kyriakou C, Rabin N, Wechalekar A, Fisher A, Sive J. The impact of continuous lenalidomide maintenance treatment on people living with multiple myeloma-a single-centre, qualitative service evaluation study. Support Care Cancer. 2024 Jul 02; 32(7):479.

Pang L, Cai C, Aggarwal P, Wang D, Vijay V, Bagam P, Blamer J, Matter A, Turner A, Ren L, Papineau K, Srinivasasainagendra V, Tiwari HK, Yang X, Schnackenberg L, Mattes W, Broeckel U. Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs-a proof-of-concept study with doxorubicin. Toxicol Sci. 2024 Jun 26; 200(1):79-94.

Arnaoutakis K, Wan Y, Elliott J, Young M, Yin Y, Leventakos K, Lin HM, Dimou A. Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC. Adv Ther. 2024 Aug; 41(8):3217-3231.

Acharya B, Saha D, Garcia Garcia N, Armstrong D, Jabali B, Hanafi M, Frett B, Ryan KR. Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors. Bioorg Med Chem. 2024 May 15; 106:117749.

Marino S, Petrusca DN, Bishop RT, Anderson JL, Sabol HM, Ashby C, Layer JH, Cesarano A, Dav? UP, Perna F, Delgado-Calle J, Chirgwin JM, Roodman GD. Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma. Haematologica. 2024 05 01; 109(5):1501-1513.

Firestone RS, McAvoy D, Shekarkhand T, Serrano E, Hamadeh I, Wang A, Zhu M, Qin WG, Patel D, Tan CR, Hultcrantz M, Mailankody S, Hassoun H, Shah US, Korde N, Maclachlan KH, Landau HJ, Scordo M, Shah GL, Lahoud OB, Giralt S, Murata K, Hosszu KK, Chung DJ, Lesokhin AM, Usmani SZ. CD8 effector T cells enhance teclistamab response in BCMA-exposed and -na?ve multiple myeloma. Blood Adv. 2024 Apr 09; 8(7):1600-1611.

Khan S, Cao L, Wiegand J, Zhang P, Zajac-Kaye M, Kaye FJ, Zheng G, Zhou D. PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer. Cells. 2024 Mar 17; 13(6).

Dinh PC, Monahan PO, Foss? SD, Sesso HD, Feldman DR, Dolan ME, Nevel K, Kincaid J, Vaughn DJ, Martin NE, Sanchez VA, Einhorn LH, Frisina R, Fung C, Kroenke K, Travis LB. Impact of pain and adverse health outcomes on long-term US testicular cancer survivors. J Natl Cancer Inst. 2024 Mar 07; 116(3):455-467.

Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V, Balev M, Patwari A, Cheruvalath H, Bhutani D, Thanendrarajan S, Dhakal B, Zangari M, Al-Hadidi S, Cooper D, Lentzsch S, van Rhee F, D'Souza A, Szabo A, Schinke C, Chakraborty R. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J. 2024 Mar 05; 14(1):35.

Hoogenboezem EN, Patel SS, Lo JH, Cavnar AB, Babb LM, Francini N, Gbur EF, Patil P, Colazo JM, Michell DL, Sanchez VM, McCune JT, Ma J, DeJulius CR, Lee LH, Rosch JC, Allen RM, Stokes LD, Hill JL, Vickers KC, Cook RS, Duvall CL. Structural optimization of siRNA conjugates for albumin binding achieves effective MCL1-directed cancer therapy. Nat Commun. 2024 Feb 21; 15(1):1581.

Das A, Fernandez NR, Levine A, Bianchi V, Stengs LK, Chung J, Negm L, Dimayacyac JR, Chang Y, Nobre L, Ercan AB, Sanchez-Ramirez S, Sudhaman S, Edwards M, Larouche V, Samuel D, Van Damme A, Gass D, Ziegler DS, Bielack SS, Koschmann C, Zelcer S, Yalon-Oren M, Campino GA, Sarosiek T, Nichols KE, Loret De Mola R, Bielamowicz K, Sabel M, Frojd CA, Wood MD, Glover JM, Lee YY, Vanan M, Adamski JK, Perreault S, Chamdine O, Hjort MA, Zapotocky M, Carceller F, Wright E, Fedorakova I, Lossos A, Tanaka R, Osborn M, Blumenthal DT, Aronson M, Bartels U, Huang A, Ramaswamy V, Malkin D, Shlien A, Villani A, Dirks PB, Pugh TJ, Getz G, Maruvka YE, Tsang DS, Ertl-Wagner B, Hawkins C, Bouffet E, Morgenstern DA, Tabori U. Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti-PD-1 Monotherapy: A Report from the International RRD Consortium. Cancer Discov. 2024 Feb 08; 14(2):258-273.

Jenkins SV, Shah S, Jamshidi-Parsian A, Mortazavi A, Kristian H, Boysen G, Vang KB, Griffin RJ, Rajaram N, Dings RPM. Acquired Radiation Resistance Induces Thiol-dependent Cisplatin Cross-resistance. Radiat Res. 2024 02 01; 201(2):174-187.

Boateng ST, Roy T, Agbo ME, Mahmud MA, Banang-Mbeumi S, Chamcheu RN, Yadav RK, Bramwell M, Pham LK, Dang DD, Jackson KE, Nagalo BM, Hill RA, Efimova T, Fotie J, Chamcheu JC. Multifaceted approach toward mapping out the anticancer properties of small molecules via in?vitro evaluation on melanoma and nonmelanoma skin cancer cells, and in silico target fishing. Chem Biol Drug Des. 2024 01; 103(1):e14418.

Jin S, Li B, Zhang B, Gao X, Jia X, Xu L, Chang S, Hu K, Wang G, Xu Z, Zhang T, Song D, Yang G, Wu X, Zhu H, Huang C, Lu Y, Shi J, Zhu W, Chen G. Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation. Acta Biochim Biophys Sin (Shanghai). 2023 12 25; 55(12):1884-1891.

Haigentz M, Lee JY, Chiao EY, Aboulafia DM, Ratner L, Ambinder RF, Baiocchi RA, Mitsuyasu RT, Wachsman W, Sparano JA, Rudek MA. Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087). Clin Cancer Res. 2023 12 15; 29(24):5038-5046.

Urbaniak A, Bathula C, Chauhan J, Rai P, Thammathong J, Clark C, Heflin B, De Loose A, Avaritt N, Rodriguez A, Tackett AJ, Sen S, Banerjee S. Synthesis and Anti-Melanoma Activity of Acryloyl Pyridinone Analogues. Chem Biodivers. 2023 Dec; 20(12):e202301550.

Mittra A, Coyne GHOS, Zlott J, Kummar S, Meehan R, Rubinstein L, Juwara L, Wilsker D, Ji J, Miller B, Navas T, Ferry-Galow KV, Voth AR, Chang TC, Jiwani S, Parchment RE, Doroshow JH, Chen AP. Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors. Cancer Chemother Pharmacol. 2024 03; 93(3):177-189.

Chakraborty R, Bhutani D, Maurer MS, Mohan M, Lentzsch S, D'Souza A. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer J. 2023 11 27; 13(1):172.

Martin TG, Moreau P, Usmani SZ, Garfall A, Mateos MV, San-Miguel JF, Oriol A, Nooka AK, Rosinol L, Chari A, Karlin L, Krishnan A, Bahlis N, Popat R, Besemer B, Mart?nez-L?pez J, Delforge M, Trancucci D, Pei L, Kobos R, Fastenau J, Gries KS, van de Donk NWCJ. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study. Clin Lymphoma Myeloma Leuk. 2024 03; 24(3):194-202.

Hanna GJ, Ahn MJ, Muzaffar J, Keam B, Bowles DW, Wong DJ, Ho AL, Kim SB, Worden F, Yun T, Meng X, Van Tornout JM, Conlan MG, Kang H. A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma. Clin Cancer Res. 2023 11 14; 29(22):4555-4563.

Firestone R, Lesokhin AM, Usmani SZ. An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple Myeloma. Blood Cancer Discov. 2023 11 01; 4(6):433-436.

Jia Y, Han L, Ramage CL, Wang Z, Weng CC, Yang L, Colla S, Ma H, Zhang W, Andreeff M, Daver N, Jain N, Pemmaraju N, Bhalla K, Mustjoki S, Zhang P, Zheng G, Zhou D, Zhang Q, Konopleva M. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells. Haematologica. 2023 10 01; 108(10):2626-2638.

Miao X, Wu LS, Lin SXW, Xu Y, Chen Y, Iwaki Y, Kobos R, Stephenson T, Kemmerer K, Uhlar CM, Banerjee A, Goldberg JD, Trancucci D, Apte A, Verona R, Pei L, Desai R, Hickey K, Su Y, Ouellet D, Samtani MN, Guo Y, Garfall AL, Krishnan A, Usmani SZ, Zhou H, Girgis S. Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1. Target Oncol. 2023 09; 18(5):667-684.

Sepahi S, Kiaei L, Kiaei M, Ghorani-Azam A. A systematic review of emerging technologies to enhance the treatment of ovarian cancer. Pharm Dev Technol. 2023 Sep; 28(7):660-677.

Lonial S, Bowser AD, Chari A, Costello C, Krishnan A, Usmani SZ. Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2023 11; 23(11):815-824.

Mian A, Naqvi SAA, Ayaz A, Husnain M, Aljama MA, Mohyuddin GR, Koehn K, Mohan M, Bin Riaz I, Chakraborty R. Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis. Leuk Res. 2023 08; 131:107324.

Diamond B, Ziccheddu B, Maclachlan K, Taylor J, Boyle E, Ossa JA, Jahn J, Affer M, Totiger TM, Coffey D, Chandhok N, Watts J, Cimmino L, Lu SX, Bolli N, Bolton K, Landau H, Park JH, Ganesh K, McPherson A, Sekeres MA, Lesokhin A, Chung DJ, Zhang Y, Ho C, Roshal M, Tyner J, Nimer S, Papaemmanuil E, Usmani S, Morgan G, Landgren O, Maura F. Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures. Blood. 2023 05 11; 141(19):2359-2371.

Azevedo-Pouly AC, Appell LE, Burdine L, Rogers LJ, Morehead LC, Fil D, Barker M, Rainwater RR, Waldrip ZJ, Koss B, Burdine MS. Chemical inhibition of DNA-PKcs impairs the activation and cytotoxicity of CD4+ helper and CD8+ effector T cells. Immunol Cell Biol. 2023 08; 101(7):663-671.

Krishnan A, Nooka AK, Chari A, Garfall AL, Martin TG, Nair S, Lin X, Qi K, Londhe A, Pei L, Ammann E, Kobos R, Smit J, Parekh T, Marshall A, Slavcev M, Usmani SZ. Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma. J Comp Eff Res. 2023 06; 12(6):e220186.

Trujillo M, Odle AK, Aykin-Burns N, Allen AR. Chemotherapy induced oxidative stress in the ovary: drug-dependent mechanisms and potential interventions?. Biol Reprod. 2023 04 11; 108(4):522-537.

Arend R, Dholakia J, Castro C, Matulonis U, Hamilton E, Jackson CG, LyBarger K, Goodman HM, Duska LR, Mahdi H, ElNaggar AC, Kagey MH, Liu A, Piper D, Barroilhet LM, Bradley W, Sachdev J, Sirard CA, O'Malley DM, Birrer M. DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma. Gynecol Oncol. 2023 05; 172:82-91.

Mateos MV, Chari A, Usmani SZ, Goldschmidt H, Weisel K, Qi K, Londhe A, Nair S, Lin X, Pei L, Ammann E, Kobos R, Smit J, Parekh T, Marshall A, Slavcev M, Moreau P. Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2023 05; 23(5):385-393.

Zhang B, Li B, Xie Y, Chang S, Xu Z, Hu H, Chen G, Zhang T, He J, Wu X, Zhu H, Lai W, Song D, Lu Y, Jia X, Zhu W, Shi J. A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway. Acta Biochim Biophys Sin (Shanghai). 2023 Feb 25; 55(2):215-224.

Lowenthal R, Taylor M, Gidden JA, Heflin B, Lay JO, Avaritt N, Tackett AJ, Urbaniak A. The mycelium of the Trametes versicolor synn. Coriolus versicolor (Turkey tail mushroom) exhibit anti-melanoma activity in vitro. Biomed Pharmacother. 2023 May; 161:114424.

Anderson JD, Davis BH, Giang G, Jones A, Lee CR, Parker K, Searcy H, Benner K, Limdi NA, Guimbellot JS. Pharmacogenetic actionability and medication prescribing in people with cystic fibrosis. Clin Transl Sci. 2023 04; 16(4):662-672.

Korde N, Usmani SZ. Cross Fire: Daratumumab-Based Therapies Are Standard of Care in Newly Diagnosed Multiple Myeloma. Hematol Oncol Stem Cell Ther. 2023 01 17; 16(2):117-123.

Ly S, Nedosekin D, Wong HK. Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin. Am J Clin Dermatol. 2023 Mar; 24(2):247-273.

Narayan HK, Sheline K, Wong V, Kuo D, Choo S, Yoon J, Leger K, Kutty S, Fradley M, Tremoulet A, Ky B, Armenian S, Guha A. Cardiovascular toxicities with pediatric tyrosine kinase inhibitor therapy: An analysis of adverse events reported to the Food and Drug Administration. Pediatr Blood Cancer. 2023 02; 70(2):e30059.

Martin T, Usmani SZ, Schecter JM, Roccia T, Jackson CC, Deraedt W, Yeh TM, Banerjee A, Pacaud L, Garrett A, Bartlett M, Haltner A, Van Sanden S, Diels J, Valluri S, Samjoo IA. Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Curr Med Res Opin. 2023 01; 39(1):81-89.

Tang C, Livingston MJ, Safirstein R, Dong Z. Cisplatin nephrotoxicity: new insights and therapeutic implications. Nat Rev Nephrol. 2023 01; 19(1):53-72.

Douglass DP, Navid F, Weiss AR. The Role of Pharmacotherapeutic Agents in Children with Desmoid Tumors. Paediatr Drugs. 2022 Sep; 24(5):433-445.

Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Mart?nez-L?pez J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022 08 11; 387(6):495-505.

Li D, Yu X, Kottur J, Gong W, Zhang Z, Storey AJ, Tsai YH, Uryu H, Shen Y, Byrum SD, Edmondson RD, Mackintosh SG, Cai L, Liu Z, Aggarwal AK, Tackett AJ, Liu J, Jin J, Wang GG. Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic. Oncogene. 2022 06; 41(24):3328-3340.

Yang F, Bettadapura SN, Smeltzer MS, Zhu H, Wang S. Pyroptosis and pyroptosis-inducing cancer drugs. Acta Pharmacol Sin. 2022 Oct; 43(10):2462-2473.

Yang F, Darsey JA, Ghosh A, Li HY, Yang MQ, Wang S. Artificial Intelligence and Cancer Drug Development. Recent Pat Anticancer Drug Discov. 2022; 17(1):2-8.

Mitra AP, Narayan VM, Mokkapati S, Miest T, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown GA, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL, Sankin AI, Boyd A, O'Donnell MA, Philipson R, Yl?-Herttuala S, Sawutz D, Parker NR, McConkey DJ, Dinney CPN. Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228.

Guo X, Xu L, Velazquez H, Chen TM, Williams RM, Heller DA, Burtness B, Safirstein R, Desir GV. Kidney-Targeted Renalase Agonist Prevents Cisplatin-Induced Chronic Kidney Disease by Inhibiting Regulated Necrosis and Inflammation. J Am Soc Nephrol. 2022 02; 33(2):342-356.

Weisel K, Martin T, Krishnan A, Jagannath S, Londhe A, Nair S, Diels J, Vogel M, Schecter JM, Banerjee A, Berdeja JG, Nesheiwat T, Garrett A, Qi K, Valluri S, Usmani SZ, Yong K. Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. Clin Drug Investig. 2022 Jan; 42(1):29-41.

Lv D, Pal P, Liu X, Jia Y, Thummuri D, Zhang P, Hu W, Pei J, Zhang Q, Zhou S, Khan S, Zhang X, Hua N, Yang Q, Arango S, Zhang W, Nayak D, Olsen SK, Weintraub ST, Hromas R, Konopleva M, Yuan Y, Zheng G, Zhou D. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity. Nat Commun. 2021 11 25; 12(1):6896.

Atrash S, Thompson-Leduc P, Tai MH, Kaila S, Gray K, Ghelerter I, Lafeuille MH, Lefebvre P, Rossi A. Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study. BMC Cancer. 2021 Nov 12; 21(1):1207.

Thummuri D, Khan S, Underwood PW, Zhang P, Wiegand J, Zhang X, Budamagunta V, Sobh A, Tagmount A, Loguinov A, Riner AN, Akki AS, Williamson E, Hromas R, Vulpe CD, Zheng G, Trevino JG, Zhou D. Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216. Mol Cancer Ther. 2022 01; 21(1):184-192.

Crowder SL, Hoogland AI, Welniak TL, LaFranchise EA, Carpenter KM, Li D, Rotroff DM, Mariam A, Pierce CM, Fischer SM, Kinney AY, Dong-Binh Tran T, Rastegari F, Berry DL, Extermann M, Kim RD, Tometich DB, Figueiredo JC, Muzaffar J, Bari S, Turner K, Weinstock GM, Jim HSL. Metagenomics and chemotherapy-induced nausea: A roadmap for future research. Cancer. 2022 02 01; 128(3):461-470.

Darrigues E, Zhao EH, De Loose A, Lee MP, Borrelli MJ, Eoff RL, Galileo DS, Penthala NR, Crooks PA, Rodriguez A. Biobanked Glioblastoma Patient-Derived Organoids as a Precision Medicine Model to Study Inhibition of Invasion. Int J Mol Sci. 2021 Oct 03; 22(19).

Sadeghi S, Kalhor H, Panahi M, Abolhasani H, Rahimi B, Kalhor R, Mehrabi A, Vahdatinia M, Rahimi H. Keratinocyte growth factor in focus: A comprehensive review from structural and functional aspects to therapeutic applications of palifermin. Int J Biol Macromol. 2021 Nov 30; 191:1175-1190.

Allen CJ, Pointer DT, Blumenthaler AN, Mehta RJ, Hoffe SE, Minsky BD, Smith GL, Blum M, Mansfield PF, Ikoma N, Das P, Ajani J, Dineen SP, Fleming JB, Badgwell BD, Pimiento JM. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional Analysis. Ann Surg. 2021 10 01; 274(4):544-548.

Shoeib AM, Yarbrough AL, Ford BM, Franks LN, Urbaniak A, Hensley LL, Benson LN, Mu S, Radominska-Pandya A, Prather PL. Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development. Life Sci. 2021 Nov 15; 285:119993.

Xu C, Meng F, Park KS, Storey AJ, Gong W, Tsai YH, Gibson E, Byrum SD, Li D, Edmondson RD, Mackintosh SG, Vedadi M, Cai L, Tackett AJ, Kaniskan H?, Jin J, Wang GG. A NSD3-targeted PROTAC suppresses NSD3 and cMyc oncogenic nodes in cancer cells. Cell Chem Biol. 2022 03 17; 29(3):386-397.e9.

Patel AD, Ravichandran S, Kheterpal M. Hedgehog inhibitors with and without adjunctive therapy in treatment of locally advanced basal cell carcinoma. Int J Dermatol. 2022 Jan; 61(1):118-124.

Zhang L, Lakkaniga NR, Bharate JB, Mcconnell N, Wang X, Kharbanda A, Leung YK, Frett B, Shah NP, Li HY. Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor. Eur J Med Chem. 2021 Dec 05; 225:113776.

Saha D, Ryan KR, Lakkaniga NR, Acharya B, Garcia NG, Smith EL, Frett B. Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. J Med Chem. 2021 08 26; 64(16):11747-11773.

Moccia M, Yang D, Lakkaniga NR, Frett B, McConnell N, Zhang L, Brescia A, Federico G, Zhang L, Salerno P, Santoro M, Li HY, Carlomagno F. Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases. Sci Rep. 2021 08 09; 11(1):16103.

Kiss RC, Xia F, Acklin S. Targeting DNA Damage Response and Repair to Enhance Therapeutic Index in Cisplatin-Based Cancer Treatment. Int J Mol Sci. 2021 Jul 30; 22(15).

Wu CE, Chang CF, Huang CY, Yang CT, Kuo CS, Hsu PC, Chang JW. Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study. BMC Cancer. 2021 Jul 27; 21(1):859.

Martin T, Usmani SZ, Schecter JM, Vogel M, Jackson CC, Deraedt W, Tian H, Yeh TM, Banerjee A, Pacaud L, Garrett A, Haltner A, Cameron C, Van Sanden S, Diels J, Valluri S, Samjoo IA. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Curr Med Res Opin. 2021 10; 37(10):1779-1788.

Mavros MN, Moris D, Karanicolas PJ, Katz MHG, O'Reilly EM, Pawlik TM. Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review. JAMA Surg. 2021 07 01; 156(7):663-672.

Penthala NR, Balasubramaniam M, Dachavaram SS, Morris EJ, Bhat-Nakshatri P, Ponder J, Jordan CT, Nakshatri H, Crooks PA. Antitumor properties of novel sesquiterpene lactone analogs as NF?B inhibitors that bind to the IKK? ubiquitin-like domain (ULD). Eur J Med Chem. 2021 Nov 15; 224:113675.

Garitano-Trojaola A, Sancho A, G?tz R, Eiring P, Walz S, Jetani H, Gil-Pulido J, Da Via MC, Teufel E, Rhodes N, Haertle L, Arellano-Viera E, Tibes R, Rosenwald A, Rasche L, Hudecek M, Sauer M, Groll J, Einsele H, Kraus S, Kort?m MK. Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia. Commun Biol. 2021 06 25; 4(1):799.

Ramaker RC, Hardigan AA, Gordon ER, Wright CA, Myers RM, Cooper SJ. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition. BMC Cancer. 2021 May 29; 21(1):632.

van der Plas E, Modi AJ, Li CK, Krull KR, Cheung YT. Cognitive Impairment in Survivors of Pediatric Acute Lymphoblastic Leukemia Treated With Chemotherapy Only. J Clin Oncol. 2021 06 01; 39(16):1705-1717.

Choi J, Manzano A, Dong W, Bellone S, Bonazzoli E, Zammataro L, Yao X, Deshpande A, Zaidi S, Guglielmi A, Gnutti B, Nagarkatti N, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Jeong K, Zhao S, Buza N, Hui P, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Ardighieri L, Bilguvar K, Quick CM, Silasi DA, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Imielinski M, Schwartz PE, Alexandrov LB, Lifton RP, Schlessinger J, Santin AD. Integrated mutational landscape analysis of uterine leiomyosarcomas. Proc Natl Acad Sci U S A. 2021 04 13; 118(15).

Antwi-Amoabeng D, Ghuman J, Ghuman J, Beutler BD, Ulanja MB, Kuriakose K, Bowman A. Ponatinib-associated panniculitis: Case report and review of the literature. Cancer Treat Res Commun. 2021; 27:100357.

Saha D, Ryan KR, Lakkaniga NR, Smith EL, Frett B. Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach. ChemMedChem. 2021 05 18; 16(10):1605-1608.

Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, Martin T, Yong K, Durie BGM, Facon T, Jurczyszyn A, Sidana S, Raje N, van de Donk N, Lonial S, Cavo M, Kristinsson SY, Lentzsch S, Hajek R, Anderson KC, Jo?o C, Einsele H, Sonneveld P, Engelhardt M, Fonseca R, Vangsted A, Weisel K, Baz R, Hungria V, Berdeja JG, Leal da Costa F, Maiolino A, Waage A, Vesole DH, Ocio EM, Quach H, Driessen C, Blad? J, Leleu X, Riva E, Bergsagel PL, Hou J, Chng WJ, Mellqvist UH, Dytfeld D, Harousseau JL, Goldschmidt H, Laubach J, Munshi NC, Gay F, Beksac M, Costa LJ, Kaiser M, Hari P, Boccadoro M, Usmani SZ, Zweegman S, Holstein S, Sezer O, Harrison S, Nahi H, Cook G, Mateos MV, Rajkumar SV, Dimopoulos MA, Richardson PG. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021 03; 22(3):e105-e118.

Gonzalvez F, Vincent S, Baker TE, Gould AE, Li S, Wardwell SD, Nadworny S, Ning Y, Zhang S, Huang WS, Hu Y, Li F, Greenfield MT, Zech SG, Das B, Narasimhan NI, Clackson T, Dalgarno D, Shakespeare WC, Fitzgerald M, Chouitar J, Griffin RJ, Liu S, Wong KK, Zhu X, Rivera VM. Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer. Cancer Discov. 2021 07; 11(7):1672-1687.

Terpos E, Mikhael J, Hajek R, Chari A, Zweegman S, Lee HC, Mateos MV, Larocca A, Ramasamy K, Kaiser M, Cook G, Weisel KC, Costello CL, Elliott J, Palumbo A, Usmani SZ. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer J. 2021 02 18; 11(2):40.

Chi RA, van der Watt P, Wei W, Birrer MJ, Leaner VD. Inhibition of Kpn?1 mediated nuclear import enhances cisplatin chemosensitivity in cervical cancer. BMC Cancer. 2021 Feb 02; 21(1):106.

Nafees S, Zafaryab M, Mehdi SH, Zia B, Rizvi MA, Khan MA. Anti-Cancer Effect of Gingerol in Cancer Prevention and Treatment. Anticancer Agents Med Chem. 2021; 21(4):428-432.

He Y, Li W, Zhang J, Yang Y, Qian Y, Zhou D. The Curcumin Analog EF24 is Highly Active Against Chemotherapy- Resistant Melanoma Cells. Curr Cancer Drug Targets. 2021; 21(7):608-618.

Roy T, Boateng ST, Banang-Mbeumi S, Singh PK, Basnet P, Chamcheu RN, Ladu F, Chauvin I, Spiegelman VS, Hill RA, Kousoulas KG, Nagalo BM, Walker AL, Fotie J, Murru S, Sechi M, Chamcheu JC. Synthesis, inverse docking-assisted identification and in vitro biological characterization of Flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and non-melanoma skin cancers. Bioorg Chem. 2021 02; 107:104595.

Chakraborty G, Patail NK, Hirani R, Nandakumar S, Mazzu YZ, Yoshikawa Y, Atiq M, Jehane LE, Stopsack KH, Lee GM, Abida W, Morris MJ, Mucci LA, Danila D, Kantoff PW. Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in BRCA2-altered Prostate Tumors. Clin Cancer Res. 2021 03 15; 27(6):1792-1806.

van Rhee F, Oksenhendler E, Srkalovic G, Voorhees P, Lim M, Dispenzieri A, Ide M, Parente S, Schey S, Streetly M, Wong R, Wu D, Maillard I, Brandstadter J, Munshi N, Bowne W, Elenitoba-Johnson KS, F?ssa A, Lechowicz MJ, Chandrakasan S, Pierson SK, Greenway A, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Chadburn A, Fajgenbaum DC. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Adv. 2020 12 08; 4(23):6039-6050.

Urbaniak A, Pi?a-Oviedo S, Yuan Y, Huczynski A, Chambers TC. Limitations of an ex vivo breast cancer model for studying the mechanism of action of the anticancer drug paclitaxel. Eur J Pharmacol. 2021 Jan 15; 891:173780.

Gressler LE, Baltz AP, Costantino RC, Slejko JF, Onukwugha E. Exploring the Use of State Medical Cannabis Legislation as a Proxy for Medical Cannabis Use Among Patients Receiving Chemotherapy. Curr Treat Options Oncol. 2020 11 19; 22(1):1.

Borcherding N, Jethava Y, Vikas P. Repurposing Anti-Cancer Drugs for COVID-19 Treatment. Drug Des Devel Ther. 2020; 14:5045-5058.

Luo MM, Usmani SZ, Mateos MV, Nahi H, Chari A, San-Miguel J, Touzeau C, Suzuki K, Kaiser M, Carson R, Heuck C, Qi M, Zhou H, Sun YN, Parasrampuria DA. Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients. J Clin Pharmacol. 2021 05; 61(5):614-627.

van Rhee F, Rossi JF, Simpson D, Foss? A, Dispenzieri A, Kuruvilla J, Goh YT, Cho SG, Capra M, Liu T, Casper C, Cavet J, Wong RS. Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab. Br J Haematol. 2021 01; 192(1):e28-e31.

Ryan KR, Giles F, Morgan GJ. Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in multiple myeloma. Eur J Haematol. 2021 Jan; 106(1):90-99.

Dimopoulos MA, ?picka I, Quach H, Oriol A, H?jek R, Garg M, Beksac M, Bringhen S, Katodritou E, Chng WJ, Leleu X, Iida S, Mateos MV, Morgan G, Vorog A, Labotka R, Wang B, Palumbo A, Lonial S. Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. J Clin Oncol. 2020 12 01; 38(34):4030-4041.

Hajiran A, Zemp L, Aydin AM, Cheryian SK, Pow-Sang JM, Chahoud J, Spiess PE. Topical chemotherapy for penile carcinoma in situ: Contemporary outcomes and reported toxicity. Urol Oncol. 2021 01; 39(1):72.e1-72.e5.

Gu C, Lu T, Wang W, Shao M, Wei R, Guo M, Li R, Qiao L, Hu Y, Zhan F, Seckinger A, Hose D, Yang Y. RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma. Leukemia. 2021 06; 35(6):1803-1807.

Atallah M, Cooper B, Mu?oz RF, Paul SM, Anguera J, Levine JD, Hammer M, Wright F, Chen LM, Melisko M, Conley YP, Miaskowski C, Dunn LB. Psychological Symptoms and Stress Are Associated With Decrements in Attentional Function in Cancer Patients Undergoing Chemotherapy. Cancer Nurs. 2020 Sep/Oct; 43(5):402-410.

Lakkaniga NR, Gunaganti N, Zhang L, Belachew B, Frett B, Leung YK, Li HY. Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation. Eur J Med Chem. 2020 Nov 15; 206:112691.

Utne I, Cooper BA, Ritchie C, Wong M, Dunn LB, Loyland B, Grov EK, Hammer MJ, Paul SM, Levine JD, Conley YP, Kober KM, Miaskowski C. Co-occurrence of decrements in physical and cognitive function is common in older oncology patients receiving chemotherapy. Eur J Oncol Nurs. 2020 Oct; 48:101823.

Jakovljevic K, Kober KM, Block A, Cooper BA, Paul SM, Hammer MJ, Cartwright F, Conley YP, Wright F, Dunn LB, Levine JD, Miaskowski C. Higher Levels of Stress Are Associated With a Significant Symptom Burden in Oncology Outpatients Receiving Chemotherapy. J Pain Symptom Manage. 2021 01; 61(1):24-31.e4.

He Y, Koch R, Budamagunta V, Zhang P, Zhang X, Khan S, Thummuri D, Ortiz YT, Zhang X, Lv D, Wiegand JS, Li W, Palmer AC, Zheng G, Weinstock DM, Zhou D. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. J Hematol Oncol. 2020 07 16; 13(1):95.

Al Hadidi S, Mims M, Miller-Chism CN, Kamble R. Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer Drugs. Ann Intern Med. 2020 08 18; 173(4):320-322.

Soleimani A, Koka M, Singh ZN, Kesari V, Badros A. Biologic Implications of t(11;14) in Multiple Myeloma Explained With a Case of Refractory Disease Sensitive to Venetoclax. Clin Lymphoma Myeloma Leuk. 2020 09; 20(9):e556-e559.

Hu L, Li B, Chen G, Song D, Xu Z, Gao L, Xi M, Zhou J, Li L, Zhang H, Feng Q, Wang Y, Lu K, Lu Y, Bu W, Wang H, Wu X, Zhu W, Shi J. A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe. J Exp Clin Cancer Res. 2020 Jun 09; 39(1):105.

Xu J, Tan HB, Zhang YJ, Tang DY, Zhan F, Li HY, Chen ZZ, Xu ZG. Catalyst-Free One-Pot Synthesis of Densely Substituted Pyrazole-Pyrazines as Anti-Colorectal Cancer Agents. Sci Rep. 2020 06 09; 10(1):9281.

Moore DC, Arnall JR, Thompson DL, Martin AL, Robinson J, Ndiaye A, Paul B, Atrash S, Bhutani M, Voorhees PM, Usmani SZ. Evaluation of Montelukast for the Prevention of Infusion-related Reactions With Daratumumab. Clin Lymphoma Myeloma Leuk. 2020 10; 20(10):e777-e781.

Al Shahrani M, Balasubramaniam M, Alshahrani MY, Saif A, Dera AA, Alasmari S, Abohassan M, Makkawi M, Radhakrishnan S, Rajagopalan P. Computational and in vitro characterization of ICY-5: A potential candidate promoting mitochondrial apoptosis via the c-MET and?STAT3 pathways. J Cell Physiol. 2021 01; 236(1):146-156.

Usmani SZ, Nahi H, Plesner T, Weiss BM, Bahlis NJ, Belch A, Voorhees PM, Laubach JP, van de Donk NWCJ, Ahmadi T, Uhlar CM, Wang J, Feng H, Qi M, Richardson PG, Lonial S. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol. 2020 Jun; 7(6):e447-e455.

Khan S, He Y, Zhang X, Yuan Y, Pu S, Kong Q, Zheng G, Zhou D. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics. Oncogene. 2020 06; 39(26):4909-4924.

Mazzu YZ, Armenia J, Nandakumar S, Chakraborty G, Yoshikawa Y, Jehane LE, Lee GM, Atiq M, Khan N, Schultz N, Kantoff PW. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer. Mol Oncol. 2020 08; 14(8):1881-1897.

Durie BGM, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV, Dispenzieri A, Kahanic SP, Thakuri MC, Reu FJ, Reynolds CM, Orlowski RZ, Barlogie B. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020 05 11; 10(5):53.

Houssein M, Khalil M, Fatfat M, Gali-Muhtasib H. Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 07; 25(7):1189-1197.

Zhang X, He Y, Zhang P, Budamagunta V, Lv D, Thummuri D, Yang Y, Pei J, Yuan Y, Zhou D, Zheng G. Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines. Eur J Med Chem. 2020 Aug 01; 199:112397.

Moccia M, Frett B, Zhang L, Lakkaniga NR, Briggs DC, Chauhan R, Brescia A, Federico G, Yan W, Santoro M, McDonald NQ, Li HY, Carlomagno F. Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology. J Med Chem. 2020 05 14; 63(9):4506-4516.

Arshad J, Ahmed J, Subhawong T, Trent JC. Progress in determining response to treatment in gastrointestinal stromal tumor. Expert Rev Anticancer Ther. 2020 04; 20(4):279-288.

Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis N, Flogegard M, Blad? J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Clemens PL, Masterson T, Lantz K, O'Rourke L, Heuck C, Qin X, Parasrampuria DA, Yuan Z, Xu S, Qi M, Usmani SZ. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020 May; 7(5):e370-e380.

Yang X, Gong Y, Waheed N, March K, Bian J, Hogan WR, Wu Y. Identifying Cancer Patients at Risk for Heart Failure Using Machine Learning Methods. AMIA Annu Symp Proc. 2019; 2019:933-941.

Khan R, Zahid U, Kollu V, Jahan N, Ali M, Tricot G, Anwer F. Therapeutic Advances in the Management of Smoldering Myeloma. Am J Ther. 2020 Mar/Apr; 27(2):e194-e203.

Zhang X, Thummuri D, Liu X, Hu W, Zhang P, Khan S, Yuan Y, Zhou D, Zheng G. Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15; 192:112186.

Zhang X, Liu X, Zhou D, Zheng G. Targeting anti-apoptotic BCL-2 family proteins for cancer treatment. Future Med Chem. 2020 04; 12(7):563-565.

Klejborowska G, Urbaniak A, Maj E, Preto J, Moshari M, Wietrzyk J, Tuszynski JA, Chambers TC, Huczynski A. Synthesis, biological evaluation and molecular docking studies of new amides of 4-chlorothiocolchicine as anticancer agents. Bioorg Chem. 2020 04; 97:103664.

Landgren CO, Chari A, Cohen YC, Spencer A, Voorhees P, Estell JA, Sandhu I, Jenner MW, Williams C, Cavo M, van de Donk NWCJ, Beksac M, Moreau P, Goldschmidt H, Kuppens S, Bandekar R, Clemens PL, Neff T, Heuck C, Qi M, Hofmeister CC. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia. 2020 07; 34(7):1840-1852.

van Rhee F, Casper C, Voorhees PM, Fayad LE, Gibson D, Kanhai K, Kurzrock R. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. Lancet Haematol. 2020 Mar; 7(3):e209-e217.

Xia J, He Y, Meng B, Chen S, Zhang J, Wu X, Zhu Y, Shen Y, Feng X, Guan Y, Kuang C, Guo J, Lei Q, Wu Y, An G, Li G, Qiu L, Zhan F, Zhou W. NEK2 induces autophagy-mediated bortezomib resistance by stabilizing Beclin-1 in multiple myeloma. Mol Oncol. 2020 04; 14(4):763-778.

Lei J, Song GT, He LJ, Luo YF, Tang DY, Lin HK, Frett B, Li HY, Chen ZZ, Xu ZG. One-pot construction of functionalized aziridines and maleimides via a novel pseudo-Knoevenagel cascade reaction. Chem Commun (Camb). 2020 Feb 18; 56(14):2194-2197.

Azizi M, Aydin AM, Hajiran A, Lai A, Kumar A, Peyton CC, Minhas S, Sonpavde GP, Chahoud J, Pagliaro LC, Necchi A, Spiess PE. Systematic Review and Meta-Analysis-Is there a Benefit in Using Neoadjuvant Systemic Chemotherapy for Locally Advanced Penile Squamous Cell Carcinoma? J Urol. 2020 06; 203(6):1147-1155.

Tonning Olsson I, Brinkman TM, Wang M, Ehrhardt MJ, Banerjee P, Mulrooney DA, Huang IC, Ness KK, Bishop MW, Srivastava D, Robison LL, Hudson MM, Krull KR. Neurocognitive and psychosocial outcomes in adult survivors of childhood soft-tissue sarcoma: A report from the St. Jude Lifetime Cohort. Cancer. 2020 04 01; 126(7):1576-1584.

Hamida RS, Abdelmeguid NE, Ali MA, Bin-Meferij MM, Khalil MI. Synthesis of Silver Nanoparticles Using a Novel Cyanobacteria Desertifilum sp. extract: Their Antibacterial and Cytotoxicity Effects. Int J Nanomedicine. 2020; 15:49-63.

Victor DW, Monsour HP, Boktour M, Lunsford K, Balogh J, Graviss EA, Nguyen DT, McFadden R, Divatia MK, Heyne K, Ankoma-Sey V, Egwim C, Galati J, Duchini A, Saharia A, Mobley C, Gaber AO, Ghobrial RM. Outcomes of Liver Transplantation for Hepatocellular Carcinoma Beyond the University of California San Francisco Criteria: A Single-center Experience. Transplantation. 2020 01; 104(1):113-121.

Chen J, Kendrick S, Qin Z. Mechanistic Insights into Chemoresistance Mediated by Oncogenic Viruses in Lymphomas. Viruses. 2019 12 16; 11(12).

Zhou J, An C, Jin X, Hu Z, Safirstein RL, Wang Y. TAK1 deficiency attenuates cisplatin-induced acute kidney injury. Am J Physiol Renal Physiol. 2020 01 01; 318(1):F209-F215.

Dillmon MS, Kennedy EB, Anderson MK, Brodersen M, Cohen H, D Amato SL, Davis P, Doshi G, Genschaw S, Makhoul I, Ormsby W, Panikkar R, Peng E, Raez LE, Ronnen EA, Wimbiscus B, Reff M. Patient-Centered Standards for Medically Integrated Dispensing: ASCO/NCODA Standards. J Clin Oncol. 2020 02 20; 38(6):633-644.

Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, Liu X, Thummuri D, Yuan Y, Wiegand JS, Pei J, Zhang W, Sharma A, McCurdy CR, Kuruvilla VM, Baran N, Ferrando AA, Kim YM, Rogojina A, Houghton PJ, Huang G, Hromas R, Konopleva M, Zheng G, Zhou D. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019 12; 25(12):1938-1947.

Kunthur A. A castrate-resistant metastatic prostate cancer patient with severe pancytopenia, successfully treated with docetaxel chemotherapy. J Oncol Pharm Pract. 2020 Jul; 26(5):1254-1258.

Czerwonka D, Urbaniak A, Sobczak S, Pi?a-Oviedo S, Chambers TC, Antoszczak M, Huczynski A. Synthesis and Anticancer Activity of Tertiary Amides of Salinomycin and Their C20-oxo Analogues. ChemMedChem. 2020 01 17; 15(2):236-246.

Cai B, Said Q, Li X, Li FY, Arcona S. Healthcare resource use and direct costs in severe aplastic anemia (SAA) patients before and after treatment with eltrombopag. J Med Econ. 2020 Mar; 23(3):243-251.

Yeh ETH, Ewer MS, Moslehi J, Dlugosz-Danecka M, Banchs J, Chang HM, Minotti G. Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology. Semin Oncol. 2019 12; 46(6):397-402.

Reid EG, Suazo A, Lensing SY, Dittmer DP, Ambinder RF, Maldarelli F, Gorelick RJ, Aboulafia D, Mitsuyasu R, Dickson MA, Wachsman W. Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi Sarcoma. Clin Cancer Res. 2020 02 01; 26(3):558-565.

Tejada M, Viele C, Kober KM, Cooper BA, Paul SM, Dunn LB, Hammer MJ, Wright F, Conley YP, Levine JD, Miaskowski C. Identification of subgroups of chemotherapy patients with distinct sleep disturbance profiles and associated co-occurring symptoms. Sleep. 2019 10 09; 42(10).

Klejborowska G, Urbaniak A, Preto J, Maj E, Moshari M, Wietrzyk J, Tuszynski JA, Chambers TC, Huczynski A. Synthesis, biological evaluation and molecular docking studies of new amides of 4-bromothiocolchicine as anticancer agents. Bioorg Med Chem. 2019 12 01; 27(23):115144.

Wright F, Dunn LB, Paul SM, Conley YP, Levine JD, Hammer MJ, Cooper BA, Miaskowski C, Kober KM. Morning Fatigue Severity Profiles in Oncology Outpatients Receiving Chemotherapy. Cancer Nurs. 2019 Sep/Oct; 42(5):355-364.

Zhao DD, Zhang L, Li WQ, Duan MH, Zhuang JL, Zhou DB. Well-differentiated systemic mastocytosis with KIT K509I mutation and uterus infiltration in an Asian woman with good response to imatinib. Chin Med J (Engl). 2019 Aug 20; 132(16):2002-2003.

Mirza MR, Bergmann TK, Mau-S?rensen M, Christensen RD, ?vall-Lundqvist E, Birrer MJ, J?rgensen M, Roed H, Malander S, Nielsen F, Lassen U, Br?sen K, Bj?rge L, M?enp?? J. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. Cancer Chemother Pharmacol. 2019 10; 84(4):791-798.

Nolden A, Joseph PV, Kober KM, Cooper BA, Paul SM, Hammer MJ, Dunn LB, Conley YP, Levine JD, Miaskowski C. Co-occurring Gastrointestinal Symptoms Are Associated With Taste Changes in Oncology Patients Receiving Chemotherapy. J Pain Symptom Manage. 2019 11; 58(5):756-765.

Strunz PP, Schmalzing M, Heidemeier A, Rasche L, Einsele H, Kort?m KM. Response to daratumumab in rituximab-resistant EBV-associated PTLD following allogenic stem cell transplantation from an EBV seronegative donor. Leuk Lymphoma. 2019 12; 60(14):3573-3576.

Rasche L, Kumar M, Gershner G, Samant R, Van Hemert R, Heidemeier A, Lapa C, Bley T, Buck A, McDonald J, Hillengass J, Epstein J, Thanendrarajan S, Schinke C, van Rhee F, Zangari M, Barlogie B, Davies FE, Morgan GJ, Weinhold N. Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis? Theranostics. 2019; 9(16):4756-4763.

Rose-Felker K, Effinger K, Kelleman MS, Sachdeva R, Meacham LR, Border WL. Improving paediatric cardiologists' awareness about the needs of childhood cancer survivors: results of a single-centre directed educational initiative. Cardiol Young. 2019 Jun; 29(6):808-812.

Van Tine BA, Govindarajan R, Attia S, Somaiah N, Barker SS, Shahir A, Barrett E, Lee P, Wacheck V, Ramage SC, Tap WD. Incidence and Management of Olaratumab Infusion-Related Reactions. J Oncol Pract. 2019 11; 15(11):e925-e933.

Usmani SZ, Nahi H, Mateos MV, van de Donk NWCJ, Chari A, Kaufman JL, Moreau P, Oriol A, Plesner T, Benboubker L, Hellemans P, Masterson T, Clemens PL, Luo M, Liu K, San-Miguel J. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. Blood. 2019 08 22; 134(8):668-677.

Bathini S, Holtzman NG, Koka R, Singh Z, Wilding E, Zou Y, Ruehle K, Kocoglu MH, Badros A, Hardy N, Yared J, Rapoport AP, Fontaine M, Emadi A, El Chaer F, Dahiya S. Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab. Am J Hematol. 2019 08; 94(8):E216-E219.

Wang R, Song S, Harada K, Ghazanfari Amlashi F, Badgwell B, Pizzi MP, Xu Y, Zhao W, Dong X, Jin J, Wang Y, Scott A, Ma L, Huo L, Vicente D, Blum Murphy M, Shanbhag N, Tatlonghari G, Thomas I, Rogers J, Kobayashi M, Vykoukal J, Estrella JS, Roy-Chowdhuri S, Han G, Zhang S, Mao X, Song X, Zhang J, Gu J, Johnson RL, Calin GA, Peng G, Lee JS, Hanash SM, Futreal A, Wang Z, Wang L, Ajani JA. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. 2020 01; 69(1):18-31.

Lee T, Christov PP, Shaw S, Tarr JC, Zhao B, Veerasamy N, Jeon KO, Mills JJ, Bian Z, Sensintaffar JL, Arnold AL, Fogarty SA, Perry E, Ramsey HE, Cook RS, Hollingshead M, Davis Millin M, Lee KM, Koss B, Budhraja A, Opferman JT, Kim K, Arteaga CL, Moore WJ, Olejniczak ET, Savona MR, Fesik SW. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer. J Med Chem. 2019 04 25; 62(8):3971-3988.

Stiles ZE, Murphy AJ, Anghelescu DL, Brown CL, Davidoff AM, Dickson PV, Glazer ES, Bishop MW, Furman WL, Pappo AS, Lucas JT, Deneve JL. Desmoplastic Small Round Cell Tumor: Long-Term Complications After Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol. 2020 Jan; 27(1):171-178.

Landau SI, Guo X, Velazquez H, Torres R, Olson E, Garcia-Milian R, Moeckel GW, Desir GV, Safirstein R. Regulated necrosis and failed repair in cisplatin-induced chronic kidney disease. Kidney Int. 2019 04; 95(4):797-814.

Ying J, Zhou D, Gu T, Huang J, Liu H. Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy. BMC Cancer. 2019 Mar 29; 19(1):288.

Arnall JR, Moore DC, Hill HL, Griffin S, Mueller MK, Lavery LA, Voorhees PM, Usmani SZ. Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses. Leuk Lymphoma. 2019 09; 60(9):2295-2298.

Einstein MH, Ndlovu N, Lee J, Stier EA, Kotzen J, Garg M, Whitney K, Lensing SY, Tunmer M, Kadzatsa W, Palefsky J, Krown SE. Cisplatin and radiation therapy in HIV-positive women with locally advanced cervical cancer in sub-Saharan Africa: A phase II study of the AIDS malignancy consortium. Gynecol Oncol. 2019 04; 153(1):20-25.

El Chaer F, Holtzman NG, Sausville EA, Law JY, Lee ST, Duong VH, Baer MR, Koka R, Singh ZN, Hardy NM, Emadi A. Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib. Acta Haematol. 2019; 141(2):107-110.

Reed L, Indra R, Mrizova I, Moserova M, Schmeiser HH, Wolf CR, Henderson CJ, Stiborova M, Phillips DH, Arlt VM. Application of hepatic cytochrome b5/P450 reductase null (HBRN) mice to study the role of cytochrome b5 in the cytochrome P450-mediated bioactivation of the anticancer drug ellipticine. Toxicol Appl Pharmacol. 2019 03 01; 366:64-74.

Birrer MJ, Betella I, Martin LP, Moore KN. Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age? Oncologist. 2019 04; 24(4):425-429.

Delgado M, Urbaniak A, Chambers TC. Contrasting effects of microtubule destabilizers versus stabilizers on induction of death in G1 phase of the cell cycle. Biochem Pharmacol. 2019 04; 162:213-223.

Adams HC, Stevenaert F, Krejcik J, Van der Borght K, Smets T, Bald J, Abraham Y, Ceulemans H, Chiu C, Vanhoof G, Usmani SZ, Plesner T, Lonial S, Nijhof I, Lokhorst HM, Mutis T, van de Donk NWCJ, Sasser AK, Casneuf T. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action. Cytometry A. 2019 03; 95(3):279-289.

Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2019 01 19; 393(10168):253-264.

Bommagani S, Penthala NR, Balasubramaniam M, Kuravi S, Caldas-Lopes E, Guzman ML, Balusu R, Crooks PA. A novel tetrazole analogue of resveratrol is a potent anticancer agent. Bioorg Med Chem Lett. 2019 01 15; 29(2):172-178.

Chacko JG, Behbehani R, Hundley KN, Al-Fanek Y. Bortezomib-Associated Optic Atrophy in Two Patients With Multiple Myeloma. J Neuroophthalmol. 2018 12; 38(4):473-475.

Desai R, Abbas SA, Goyal H, Durairaj A, Fong HK, Hung O, Sachdeva R, Barac A, Yusuf SW, Kumar G. Frequency of Takotsubo Cardiomyopathy in Adult Patients Receiving Chemotherapy (from a 5-Year Nationwide Inpatient Study). Am J Cardiol. 2019 02 15; 123(4):667-673.

Gu C, Jing X, Holman C, Sompallae R, Zhan F, Tricot G, Yang Y, Janz S. Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma. BMC Cancer. 2018 Nov 21; 18(1):1152.

Lubet RA, Beger RD, Miller MS, Luster J, Seifried HE, Grubbs CJ. Comparison of Effects of Diet on Mammary Cancer: Efficacy of Various Preventive Agents and Metabolomic Changes of Different Diets and Agents. Cancer Prev Res (Phila). 2018 12; 11(12):831-840.

Gunaganti N, Kharbanda A, Lakkaniga NR, Zhang L, Cooper R, Li HY, Frett B. Catalyst free, C-3 functionalization of imidazo[1,2-a]pyridines to rapidly access new chemical space for drug discovery efforts. Chem Commun (Camb). 2018 Nov 15; 54(92):12954-12957.

van der Meij BS, Deutz NEP, Rodriguez RER, Engelen MPKJ. Increased amino acid turnover and myofibrillar protein breakdown in advanced cancer are associated with muscle weakness and impaired physical function. Clin Nutr. 2019 10; 38(5):2399-2407.

Abraham A, Kattoor AJ, Saldeen T, Mehta JL. Vitamin E and its anticancer effects. Crit Rev Food Sci Nutr. 2019; 59(17):2831-2838.

Nafees S, Mehdi SH, Zafaryab M, Zeya B, Sarwar T, Rizvi MA. Synergistic Interaction of Rutin and Silibinin on Human Colon Cancer?Cell?Line. Arch Med Res. 2018 05; 49(4):226-234.

Stambough K, Childress KJ. Ovarian conservation in management of pediatric gynecology malignancies. Curr Opin Obstet Gynecol. 2018 10; 30(5):316-325.

Miousse IR, Tobacyk J, Quick CM, Jamshidi-Parsian A, Skinner CM, Kore R, Melnyk SB, Kutanzi KR, Xia F, Griffin RJ, Koturbash I. Modulation of dietary methionine intake elicits potent, yet distinct, anticancer effects on primary versus metastatic tumors. Carcinogenesis. 2018 09 21; 39(9):1117-1126.

Yan W, Lakkaniga NR, Carlomagno F, Santoro M, McDonald NQ, Lv F, Gunaganti N, Frett B, Li HY. Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application. J Med Chem. 2019 02 28; 62(4):1731-1760.

Majcher U, Urbaniak A, Maj E, Moshari M, Delgado M, Wietrzyk J, Bartl F, Chambers TC, Tuszynski JA, Huczynski A. Synthesis, antiproliferative activity and molecular docking of thiocolchicine urethanes. Bioorg Chem. 2018 12; 81:553-566.

van Rhee F, Voorhees P, Dispenzieri A, Foss? A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018 11 15; 132(20):2115-2124.

McCarthy MS, Matthews EE, Battaglia C, Meek PM. Feasibility of a Telemedicine-Delivered Cognitive Behavioral Therapy for Insomnia in Rural Breast Cancer Survivors. Oncol Nurs Forum. 2018 09 01; 45(5):607-618.

Ghoneum A, Afify H, Salih Z, Kelly M, Said N. Role of tumor microenvironment in the pathobiology of ovarian cancer: Insights and therapeutic opportunities. Cancer Med. 2018 10; 7(10):5047-5056.

Fisher BT, Robinson PD, Lehrnbecher T, Steinbach WJ, Zaoutis TE, Phillips B, Sung L. Risk Factors for Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review. J Pediatric Infect Dis Soc. 2018 Aug 17; 7(3):191-198.

Janganati V, Ponder J, Balasubramaniam M, Bhat-Nakshatri P, Bar EE, Nakshatri H, Jordan CT, Crooks PA. MMB triazole analogs are potent NF-?B inhibitors and anti-cancer agents against both hematological and solid tumor cells. Eur J Med Chem. 2018 Sep 05; 157:562-581.

Kapoor R, Robinson KA, Badgwell B. Nephrotoxic synergism of cisplatin and mitomycin-C for hyperthermic intraperitoneal chemotherapy and cytoreductive surgery. Int J Hyperthermia. 2018 08; 34(5):601.

Spencer Noakes TL, Przybycien TS, Forwell A, Nicholls C, Zhou YQ, Butcher DT, Weksberg R, Guger SL, Spiegler BJ, Schachar RJ, Hitzler J, Ito S, van der Plas E, Nieman BJ. Brain Development and Heart Function after Systemic Single-Agent Chemotherapy in a Mouse Model of Childhood Leukemia Treatment. Clin Cancer Res. 2018 12 01; 24(23):6040-6052.

Antoszczak M, Urbaniak A, Delgado M, Maj E, Borgstr?m B, Wietrzyk J, Huczynski A, Yuan Y, Chambers TC, Strand D. Biological activity of doubly modified salinomycin analogs - Evaluation in?vitro and ex?vivo. Eur J Med Chem. 2018 Aug 05; 156:510-523.

Hussain SS, Huang SB, Bedolla RG, Rivas P, Basler JW, Swanson GP, Hui-Ming Huang T, Narayanasamy G, Papanikolaou N, Miyamoto H, Yeh IT, Reddick RL, Pollock BH, Ghosh R, Kumar AP. Suppression of ribosomal protein RPS6KB1 by Nexrutine increases sensitivity of prostate tumors to radiation. Cancer Lett. 2018 10 01; 433:232-241.

He LJ, Yang DL, Li SQ, Zhang YJ, Tang Y, Lei J, Frett B, Lin HK, Li HY, Chen ZZ, Xu ZG. Facile construction of fused benzimidazole-isoquinolinones that induce cell-cycle arrest and apoptosis in colorectal cancer cells. Bioorg Med Chem. 2018 08 07; 26(14):3899-3908.

Kaur G, Cholia RP, Joshi G, Amrutkar SM, Kalra S, Mantha AK, Banerjee UC, Kumar R. Anticancer activity of dihydropyrazolo[1,5-c]quinazolines against rat C6 glioma cells via inhibition of topoisomerase II. Arch Pharm (Weinheim). 2018 Jun; 351(6):e1800023.

Eshghi N, Lundeen TF, MacKinnon L, Avery R, Kuo PH. 18F-FDG PET/CT for Monitoring Response of Merkel Cell Carcinoma to the Novel Programmed Cell Death Ligand 1 Inhibitor Avelumab. Clin Nucl Med. 2018 May; 43(5):e142-e144.

El Chaer F, Singh ZN, Zou Y, Mohindra P, Baer MR, Law JY. Acute Onset Unilateral Proptosis. Am J Med. 2018 08; 131(8):e337-e338.

Khan M, Stone K, van Rhee F. Daratumumab for POEMS Syndrome. Mayo Clin Proc. 2018 04; 93(4):542-544.

Moore KN, Birrer MJ. Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations. Oncologist. 2018 06; 23(6):697-703.

Parrales A, McDonald P, Ottomeyer M, Roy A, Shoenen FJ, Broward M, Bruns T, Thamm DH, Weir SJ, Neville KA, Iwakuma T, Fulbright JM. Comparative oncology approach to drug repurposing in osteosarcoma. PLoS One. 2018; 13(3):e0194224.

Al-Tamimi J, Semlali A, Hassan I, Ebaid H, Alhazza IM, Mehdi SH, Al-Khalifa M, Alanazi MS. Samsum Ant Venom Exerts Anticancer Activity Through Immunomodulation In Vitro and In Vivo. Cancer Biother Radiopharm. 2018 Mar; 33(2):65-73.

Bharate JB, McConnell N, Naresh G, Zhang L, Lakkaniga NR, Ding L, Shah NP, Frett B, Li HY. Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT. Sci Rep. 2018 02 27; 8(1):3722.

Gao L, Li B, Yang G, Liu P, Lan X, Chang S, Tao Y, Xu Z, Xie B, Sun X, Wang Y, Hu L, Yu D, Xie Y, Bu W, Wu X, Zhu W, Shi J. Dual inhibition of mTORC1/2 by DCZ0358 induces cytotoxicity in multiple myeloma and overcomes the protective effect of the bone marrow microenvironment. Cancer Lett. 2018 05 01; 421:135-144.

Zeidan YH, Habib JG, Ameye L, Paesmans M, de Azambuja E, Gelber RD, Campbell I, Nordenskj?ld B, Guti?rez J, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Joseph DJ, Crown J, Piccart-Gebhart M, Francis PA. Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial. Int J Radiat Oncol Biol Phys. 2018 06 01; 101(2):316-324.

Goyal S, Uwaydat SH. Epidermal Growth Factor Receptor Inhibitor Induced Trichomegaly and Poliosis. Ophthalmology. 2018 02; 125(2):294.

Fok JHL, Hedayat S, Zhang L, Aronson LI, Mirabella F, Pawlyn C, Bright MD, Wardell CP, Keats JJ, De Billy E, Rye CS, Chessum NEA, Jones K, Morgan GJ, Eccles SA, Workman P, Davies FE. HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target. Clin Cancer Res. 2018 05 15; 24(10):2395-2407.

Sharp CN, Doll MA, Megyesi J, Oropilla GB, Beverly LJ, Siskind LJ. Subclinical kidney injury induced by repeated cisplatin administration results in progressive chronic kidney disease. Am J Physiol Renal Physiol. 2018 07 01; 315(1):F161-F172.

Zafar MK, Maddukuri L, Ketkar A, Penthala NR, Reed MR, Eddy S, Crooks PA, Eoff RL. A Small-Molecule Inhibitor of Human DNA Polymerase ? Potentiates the Effects of Cisplatin in Tumor Cells. Biochemistry. 2018 02 20; 57(7):1262-1273.

Maarouf M, Alexander C, Shi VY. Nivolumab reactivation of hypertrophic lichen planus, a case report and review of published literature. Dermatol Online J. 2018 Jan 15; 24(1).

Khan MA, Zafaryab M, Mehdi SH, Ahmad I, Rizvi MMA. Physicochemical Characterization of Curcumin Loaded Chitosan Nanoparticles: Implications in Cervical Cancer. Anticancer Agents Med Chem. 2018; 18(8):1131-1137.

Awad R, Andrade JCB, Mousa H, Mahmoud F. Invasive Basal Cell Carcinoma of the Skin Treated Successfully with Vismodegib: A Case Report. Perm J. 2018; 22:17-181.

Pina-Oviedo S, Miranda RN, Medeiros LJ. Cancer Therapy-associated Lymphoproliferative Disorders: An Under-recognized Type of Immunodeficiency-associated Lymphoproliferative Disorder. Am J Surg Pathol. 2018 Jan; 42(1):116-129.

Madadi NR, Penthala NR, Ketkar A, Eoff RL, Trujullo-Alonso V, Guzman ML, Crooks PA. Synthesis and Evaluation of 2-Naphthaleno trans-Stilbenes and Cyanostilbenes as Anticancer Agents. Anticancer Agents Med Chem. 2018; 18(4):556-564.

Qi R, Wang Y, Bruno PM, Xiao H, Yu Y, Li T, Lauffer S, Wei W, Chen Q, Kang X, Song H, Yang X, Huang X, Detappe A, Matulonis U, Pepin D, Hemann MT, Birrer MJ, Ghoroghchian PP. Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nat Commun. 2017 12 18; 8(1):2166.

Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular Complications of Cancer?Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. J Am Coll Cardiol. 2017 Nov 14; 70(20):2536-2551.

Campbell JP, Heaney JLJ, Pandya S, Afzal Z, Kaiser M, Owen R, Child JA, Cairns DA, Gregory W, Morgan GJ, Jackson GH, Bunce CM, Drayson MT. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study. Lancet Haematol. 2017 Dec; 4(12):e584-e594.

Emadi A, Law JY, Strovel ET, Lapidus RG, Jeng LJB, Lee M, Blitzer MG, Carter-Cooper BA, Sewell D, Van Der Merwe I, Philip S, Imran M, Yu SL, Li H, Amrein PC, Duong VH, Sausville EA, Baer MR, Fathi AT, Singh Z, Bentzen SM. Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia. Cancer Chemother Pharmacol. 2018 01; 81(1):217-222.

Nickoloff JA, Jones D, Lee SH, Williamson EA, Hromas R. Drugging the Cancers Addicted to DNA Repair. J Natl Cancer Inst. 2017 11 01; 109(11).

Ward Sullivan C, Leutwyler H, Dunn LB, Miaskowski C. A review of the literature on symptom clusters in studies that included oncology patients receiving primary or adjuvant chemotherapy. J Clin Nurs. 2018 Feb; 27(3-4):516-545.

Samanta D. Surendra Nath Sehgal: A pioneer in rapamycin discovery. Indian J Cancer. 2017 Oct-Dec; 54(4):697-698.

Zafar MK, Eoff RL. Translesion DNA Synthesis in Cancer: Molecular Mechanisms and Therapeutic Opportunities. Chem Res Toxicol. 2017 11 20; 30(11):1942-1955.

Wu X, Zhang LS, Toombs J, Kuo YC, Piazza JT, Tuladhar R, Barrett Q, Fan CW, Zhang X, Walensky LD, Kool M, Cheng SY, Brekken R, Opferman JT, Green DR, Moldoveanu T, Lum L. Extra-mitochondrial prosurvival BCL-2 proteins regulate gene transcription by inhibiting the SUFU?tumour suppressor. Nat Cell Biol. 2017 Oct; 19(10):1226-1236.

Kothari A, Caradine KD, Rico Crescencio JC, Sasapu A, Veeraputhiran MK, Jethava Y, Burgess MJ. Cytomegalovirus appendicitis after hematopoietic stem cell transplantation. Transpl Infect Dis. 2017 Oct; 19(5).

Sullivan CW, Leutwyler H, Dunn LB, Cooper BA, Paul SM, Levine JD, Hammer M, Conley YP, Miaskowski CA. Stability of Symptom Clusters in Patients With Breast Cancer Receiving Chemotherapy. J Pain Symptom Manage. 2018 01; 55(1):39-55.

Boegemann M, Aydin AM, Bagrodia A, Krabbe LM. Prospects and progress of immunotherapy for bladder cancer. Expert Opin Biol Ther. 2017 11; 17(11):1417-1431.

Lu YC, Parker LL, Lu T, Zheng Z, Toomey MA, White DE, Yao X, Li YF, Robbins PF, Feldman SA, van der Bruggen P, Klebanoff CA, Goff SL, Sherry RM, Kammula US, Yang JC, Rosenberg SA. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. J Clin Oncol. 2017 Oct 10; 35(29):3322-3329.

Mendonca MS, Turchan WT, Alpuche ME, Watson CN, Estabrook NC, Chin-Sinex H, Shapiro JB, Imasuen-Williams IE, Rangel G, Gilley DP, Huda N, Crooks PA, Shapiro RH. DMAPT inhibits NF-?B activity and increases sensitivity of prostate cancer cells to X-rays in vitro and in tumor xenografts in vivo. Free Radic Biol Med. 2017 11; 112:318-326.

Fader AN, Bergstrom J, Jernigan A, Tanner EJ, Roche KL, Stone RL, Levinson KL, Ricci S, Wethingon S, Wang TL, Shih IM, Yang B, Zhang G, Armstrong DK, Gaillard S, Michener C, DeBernardo R, Rose PG. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? Gynecol Oncol. 2017 10; 147(1):85-91.

Kovalchuk A, Ilnytskyy Y, Rodriguez-Juarez R, Shpyleva S, Melnyk S, Pogribny I, Katz A, Sidransky D, Kovalchuk O, Kolb B. Chemo brain or tumor brain - that is the question: the presence of extracranial tumors profoundly affects molecular processes in the prefrontal cortex of TumorGraft mice. Aging (Albany NY). 2017 07 29; 9(7):1660-1676.

Kendrick S, Muranyi A, Gokhale V, Hurley LH, Rimsza LM. Simultaneous Drug Targeting of the Promoter MYC G-Quadruplex and BCL2 i-Motif in Diffuse Large B-Cell Lymphoma Delays Tumor Growth. J Med Chem. 2017 08 10; 60(15):6587-6597.

Wang J, Cheng P, Pavlyukov MS, Yu H, Zhang Z, Kim SH, Minata M, Mohyeldin A, Xie W, Chen D, Goidts V, Frett B, Hu W, Li H, Shin YJ, Lee Y, Nam DH, Kornblum HI, Wang M, Nakano I. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2. J Clin Invest. 2017 Aug 01; 127(8):3075-3089.

Nima ZA, Alwbari AM, Dantuluri V, Hamzah RN, Sra N, Motwani P, Arnaoutakis K, Levy RA, Bohliqa AF, Nedosekin D, Zharov VP, Makhoul I, Biris AS. Targeting nano drug delivery to cancer cells using tunable, multi-layer, silver-decorated gold nanorods. J Appl Toxicol. 2017 Dec; 37(12):1370-1378.

Ikoma N, Das P, Blum M, Estrella JS, Devine CE, Wang X, Fournier K, Mansfield P, Minsky BD, Ajani J, Badgwell BD. Preoperative Chemoradiation Therapy Does Not Increase Risk of Anastomotic Leak in Patients With Gastric Cancer. Int J Radiat Oncol Biol Phys. 2017 11 01; 99(3):660-666.

Miaskowski C, Wong ML, Cooper BA, Mastick J, Paul SM, Possin K, Steinman M, Cataldo J, Dunn LB, Ritchie C. Distinct Physical Function Profiles in Older Adults Receiving Cancer Chemotherapy. J Pain Symptom Manage. 2017 09; 54(3):263-272.

Badgwell B, Blum M, Das P, Estrella J, Wang X, Fournier K, Royal R, Mansfield P, Ajani J. Lessons learned from a phase II clinical trial of laparoscopic HIPEC for gastric cancer. Surg Endosc. 2018 01; 32(1):512.

Firwana B, Avaritt N, Shields B, Ravilla R, Makhoul I, Hutchins L, Tackett AJ, Mahmoud F. Do checkpoint inhibitors rely on gut microbiota to fight cancer? J Oncol Pharm Pract. 2018 Sep; 24(6):468-472.

Geer EB, Shafiq I, Gordon MB, Bonert V, Ayala A, Swerdloff RS, Katznelson L, Lalazar Y, Manuylova E, Pulaski-Liebert KJ, Carmichael JD, Hannoush Z, Surampudi V, Broder MS, Cherepanov D, Eagan M, Lee J, Said Q, Neary MP, Biller BMK. BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY. Endocr Pract. 2017 Aug; 23(8):962-970.

Usmani SZ, Diels J, Ito T, Mehra M, Khan I, Lam A. Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison. Am J Hematol. 2017 Aug; 92(8):E146-E152.

Chen G, Xu Z, Chang G, Hou J, Hu L, Zhang Y, Yu D, Li B, Chang S, Xie Y, Zhang Y, Wei R, Wu H, Xiao W, Sun X, Tao Y, Gao L, Dai B, Shi J, Zhu W. The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells. Oncol Rep. 2017 Jul; 38(1):488-496.

Delgado-Calle J, Anderson J, Cregor MD, Condon KW, Kuhstoss SA, Plotkin LI, Bellido T, Roodman GD. Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth. Leukemia. 2017 12; 31(12):2686-2694.

Bommagani S, Ponder J, Penthala NR, Janganati V, Jordan CT, Borrelli MJ, Crooks PA. Indole carboxylic acid esters of melampomagnolide B are potent anticancer agents against both hematological and solid tumor cells. Eur J Med Chem. 2017 Aug 18; 136:393-405.

Janganati V, Ponder J, Thakkar S, Jordan CT, Crooks PA. Succinamide derivatives of melampomagnolide B and their anti-cancer activities. Bioorg Med Chem. 2017 07 15; 25(14):3694-3705.

Ward Sullivan C, Leutwyler H, Dunn LB, Cooper BA, Paul SM, Conley YP, Levine JD, Miaskowski CA. Differences in symptom clusters identified using symptom occurrence rates versus severity ratings in patients with breast cancer undergoing chemotherapy. Eur J Oncol Nurs. 2017 Jun; 28:122-132.

Moore KN, Borghaei H, O'Malley DM, Jeong W, Seward SM, Bauer TM, Perez RP, Matulonis UA, Running KL, Zhang X, Ponte JF, Ruiz-Soto R, Birrer MJ. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor a-targeting antibody-drug conjugate, in patients with solid tumors. Cancer. 2017 Aug 15; 123(16):3080-3087.

Mahmoud F, Wilkinson JT, Gizinski A, Viswamitra S, Gokden N, Vander Schilden J. Could knee inflammatory synovitis be induced by pembrolizumab? J Oncol Pharm Pract. 2018 Jul; 24(5):389-392.

Pan J, Li D, Xu Y, Zhang J, Wang Y, Chen M, Lin S, Huang L, Chung EJ, Citrin DE, Wang Y, Hauer-Jensen M, Zhou D, Meng A. Inhibition of Bcl-2/xl With ABT-263 Selectively Kills Senescent Type II Pneumocytes and Reverses Persistent Pulmonary Fibrosis Induced by Ionizing Radiation in Mice. Int J Radiat Oncol Biol Phys. 2017 10 01; 99(2):353-361.

Gockley A, Melamed A, Bregar AJ, Clemmer JT, Birrer M, Schorge JO, Del Carmen MG, Rauh-Hain JA. Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer. Obstet Gynecol. 2017 03; 129(3):439-447.

Kreys ED, Frei CR, Villarreal SM, Bollinger MJ, Jones X, Koeller JM. Evaluation of Long-Term Chronic Myeloid Leukemia Treatment Practices with Tyrosine Kinase Inhibitors in a National Cohort of Veterans. Pharmacotherapy. 2017 03; 37(3):278-286.

Xiao H, Qi R, Li T, Awuah SG, Zheng Y, Wei W, Kang X, Song H, Wang Y, Yu Y, Bird MA, Jing X, Yaffe MB, Birrer MJ, Ghoroghchian PP. Maximizing Synergistic Activity When Combining RNAi and Platinum-Based Anticancer Agents. J Am Chem Soc. 2017 03 01; 139(8):3033-3044.

Xia J, Xu H, Zhang X, Allamargot C, Coleman KL, Nessler R, Frech I, Tricot G, Zhan F. Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid. EBioMedicine. 2017 Apr; 18:41-49.

Oakley E, Bellnier DA, Hutson A, Wrazen B, Arshad H, Quon H, Shafirstein G. Surface markers for guiding cylindrical diffuser fiber insertion in interstitial photodynamic therapy of head and neck cancer. Lasers Surg Med. 2017 08; 49(6):599-608.

Matin A, Sharma S, Mathur P, Apewokin SK. Myelosuppression-sparing treatment of central nervous system nocardiosis in a multiple myeloma patient utilizing a tedizolid-based regimen: a case report. Int J Antimicrob Agents. 2017 Apr; 49(4):488-492.

Socola F, Hawes V, Lobo RH, Sasapu A. Imatinib-Associated Tumor Lysis Syndrome in a Patient With Myeloid Neoplasm With Eosinophilia and PDGFRA Rearrangement: A Case Report and Review of the Literature. J Glob Oncol. 2018 09; 4:1-4.

Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, Chen X, Duncan JS, Whittle MC, Angus SP, Velarde SH, Golitz BT, He X, Santos C, Darr DB, Gallagher K, Graves LM, Perou CM, Carey LA, Earp HS, Johnson GL. Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex. Cancer Discov. 2017 03; 7(3):302-321.

Khan MA, Zafaryab M, Mehdi SH, Quadri J, Rizvi MM. Characterization and carboplatin loaded chitosan nanoparticles for the chemotherapy against breast cancer in vitro studies. Int J Biol Macromol. 2017 Apr; 97:115-122.

Tirumani SH, Baheti AD, Tirumani H, O'Neill A, Jagannathan JP. Update on Gastrointestinal Stromal Tumors for Radiologists. Korean J Radiol. 2017 Jan-Feb; 18(1):84-93.

Kieber-Emmons T, Makhoul I, Pennisi A, Siegel ER, Emanuel PD, Monzavi-Karbassi B, Steplewski Z, Beck JT, Hutchins LF. Managing Expectations in the Transition to Proof of Concept Studies. Rev Recent Clin Trials. 2017; 12(2):111-123.

Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr 01; 35(10):1112-1118.

Albayati ZAF, Janganati V, Chen Z, Ponder J, Breen PJ, Jordan CT, Crooks PA. Identification of a melampomagnolide B analog as a potential lead molecule for treatment of acute myelogenous leukemia. Bioorg Med Chem. 2017 02 01; 25(3):1235-1241.

Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R, Orlowski RZ, Barlogie B, Dispenzieri A. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017 02 04; 389(10068):519-527.

Kamel MK, Nasar A, Stiles BM, Altorki NK, Port JL. Video-Assisted Thoracoscopic Lobectomy Is the Preferred Approach Following Induction Chemotherapy. J Laparoendosc Adv Surg Tech A. 2017 May; 27(5):495-500.

Lee T, Bian Z, Zhao B, Hogdal LJ, Sensintaffar JL, Goodwin CM, Belmar J, Shaw S, Tarr JC, Veerasamy N, Matulis SM, Koss B, Fischer MA, Arnold AL, Camper DV, Browning CF, Rossanese OW, Budhraja A, Opferman J, Boise LH, Savona MR, Letai A, Olejniczak ET, Fesik SW. Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors. FEBS Lett. 2017 Jan; 591(1):240-251.

Demaria M, O'Leary MN, Chang J, Shao L, Liu S, Alimirah F, Koenig K, Le C, Mitin N, Deal AM, Alston S, Academia EC, Kilmarx S, Valdovinos A, Wang B, de Bruin A, Kennedy BK, Melov S, Zhou D, Sharpless NE, Muss H, Campisi J. Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse. Cancer Discov. 2017 02; 7(2):165-176.

Wolfe AR, Trenton NJ, Debeb BG, Larson R, Ruffell B, Chu K, Hittelman W, Diehl M, Reuben JM, Ueno NT, Woodward WA. Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models. Oncotarget. 2016 Dec 13; 7(50):82482-82492.

Xi JB, Fang YF, Frett B, Zhu ML, Zhu T, Kong YN, Guan FJ, Zhao Y, Zhang XW, Li HY, Ma ML, Hu W. Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with in?vitro and in?vivo antitumor activities. Eur J Med Chem. 2017 Jan 27; 126:1083-1106.

Bansal M, Abdallah AO, Pennisi A, Arnaoutakis K, Makhoul I, Mehta P. Improving Communication on Intent of Chemotherapy Using QOPI Scores and PDSA Cycles. J Cancer Educ. 2016 12; 31(4):736-741.

Hinduja A, Limaye K, Ravilla R, Sasapu A, Papanikolaou X, Wei L, Torbey M, Waheed S. Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study. PLoS One. 2016; 11(11):e0166627.

Chu R, Alford SE, Hart K, Kothari A, Mackintosh SG, Kovak MR, Chambers TC. Mitotic arrest-induced phosphorylation of Mcl-1 revisited using two-dimensional gel electrophoresis and phosphoproteomics: nine phosphorylation sites identified. Oncotarget. 2016 Nov 29; 7(48):78958-78970.

Lahiani MH, Eassa S, Parnell C, Nima Z, Ghosh A, Biris AS, Khodakovskaya MV. Carbon nanotubes as carriers of Panax ginseng metabolites and enhancers of ginsenosides Rb1 and Rg1 anti-cancer activity. Nanotechnology. 2017 Jan 06; 28(1):015101.

Wang Y, Chang J, Liu X, Zhang X, Zhang S, Zhang X, Zhou D, Zheng G. Discovery of piperlongumine as a potential novel lead for the development of senolytic agents. Aging (Albany NY). 2016 11 19; 8(11):2915-2926.

Xie B, Xu Z, Hu L, Chen G, Wei R, Yang G, Li B, Chang G, Sun X, Wu H, Zhang Y, Dai B, Tao Y, Shi J, Zhu W. Pterostilbene Inhibits Human Multiple Myeloma Cells via ERK1/2 and JNK Pathway In Vitro and In Vivo. Int J Mol Sci. 2016 Nov 17; 17(11).

Jacobs RW, Awan FT, Leslie LA, Usmani SZ, Ghosh N. The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia. Expert Rev Hematol. 2016 Dec; 9(12):1177-1187.

Boccia A, Virata C, Lindner D, English N, Pathan N, Brickelmaier M, Hu X, Gardner JL, Peng L, Wang X, Zhang X, Yang L, Perron K, Yco G, Kelly R, Gamez J, Scripps T, Bennett D, Joseph IB, Baker DP. Peginterferon Beta-1a Shows Antitumor Activity as a Single Agent and Enhances Efficacy of Standard of Care Cancer Therapeutics in Human Melanoma, Breast, Renal, and Colon Xenograft Models. J Interferon Cytokine Res. 2017 01; 37(1):20-31.

Mohan M, Fogel B, Eluvathingal T, Schinke C, Kothari A. Gastrointestinal histoplasmosis in a patient after autologous stem cell transplant for multiple myeloma. Transpl Infect Dis. 2016 Dec; 18(6):939-941.

Mateo AM, Pezzi TA, Sundermeyer M, Kelley CA, Klimberg VS, Pezzi CM. Chemotherapy Significantly Improves Survival for Patients with T1c-T2N0M0 Medullary Breast Cancer: 3739 Cases From the National Cancer Data Base. Ann Surg Oncol. 2017 Apr; 24(4):1050-1056.

Mousavian Z, Nowzari-Dalini A, Stam RW, Rahmatallah Y, Masoudi-Nejad A. Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia. Cell Oncol (Dordr). 2017 Feb; 40(1):33-45.

McCourt CK, Deng W, Dizon DS, Lankes HA, Birrer MJ, Lomme MM, Powell MA, Kendrick JE, Saltzman JN, Warshal D, Tenney ME, Kushner DM, Aghajanian C. A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 Jan; 144(1):101-106.

Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016 10; 14(10):1213-1224.

Abe J, Martin JF, Yeh ET. The Future of Onco-Cardiology: We Are Not Just "Side Effect Hunters". Circ Res. 2016 09 30; 119(8):896-9.

Mohan M, Shalin SC, Kothari A, Rico JC, Caradine K, Burgess M. Lasiodiplodia species fungal osteomyelitis in a multiple myeloma patient. Transpl Infect Dis. 2016 Oct; 18(5):761-764.

Kamel MK, Rahouma M, Ghaly G, Nasar A, Port JL, Stiles BM, Nguyen AB, Altorki NK, Lee PC. Clinical Predictors of Persistent Mediastinal Nodal Disease After Induction Therapy for Stage IIIA N2 Non-Small Cell Lung Cancer. Ann Thorac Surg. 2017 Jan; 103(1):281-286.

Khan MA, Zafaryab M, Mehdi SH, Ahmad I, Rizvi MM. Characterization and anti-proliferative activity of curcumin loaded chitosan nanoparticles in cervical cancer. Int J Biol Macromol. 2016 Dec; 93(Pt A):242-253.

Haverkos BM, Gru AA, Geyer SM, Bingman AK, Hemminger JA, Mishra A, Wong HK, Pancholi P, Freud AG, Caligiuri MA, Baiocchi RA, Porcu P. Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2016 08; 16 Suppl:S181-S190.e4.

Sriskandarajah P, Pawlyn C, Mohammed K, Dearden CE, Davies FE, Morgan GJ, Boyd KD, Kaiser MF. The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience. Leuk Lymphoma. 2017 02; 58(2):494-497.

Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, Wakefield A, Fousek K, Bielamowicz K, Chow KK, Brawley VS, Byrd TT, Krebs S, Gottschalk S, Wels WS, Baker ML, Dotti G, Mamonkin M, Brenner MK, Orange JS, Ahmed N. Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2016 08 01; 126(8):3036-52.

Wilbur MB, Birrer MJ, Spriggs DR. CLINICAL DECISIONS. Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 Jul 14; 375(2):177-9.

Casserly EA, Rogers SE, Keisner SV. Lack of interaction between enzalutamide and warfarin in a metastatic castration-resistant prostate cancer patient. J Oncol Pharm Pract. 2017 Jan; 23(1):68-70.

Montales MT, Melnyk SB, Liu SJ, Simmen FA, Liu YL, Simmen RC. Metabolic history impacts mammary tumor epithelial hierarchy and early drug response in mice. Endocr Relat Cancer. 2016 09; 23(9):677-90.

Atrash S, Makhoul I, Mizell JS, Hutchins L, Mahmoud F. Response of metastatic mucosal melanoma to immunotherapy: It can get worse before it gets better. J Oncol Pharm Pract. 2017 Apr; 23(3):215-219.

Mahmoud F, Abdallah AO, Arnaoutakis K, Makhoul I. Metastatic Renal Cell Carcinoma Presenting as Painful Chewing Successfully Treated with Combined Nivolumab and Sunitinib. Perm J. 2016; 20(3):15-149.

Ihemelandu C, Mavros MN, Sugarbaker P. Adverse Events Postoperatively Had No Impact on Long-Term Survival of Patients Treated with Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Appendiceal Cancer with Peritoneal Metastases. Ann Surg Oncol. 2016 12; 23(13):4231-4237.

Bachegowda L, Morrone K, Winski SL, Mantzaris I, Bartenstein M, Ramachandra N, Giricz O, Sukrithan V, Nwankwo G, Shahnaz S, Bhagat T, Bhattacharyya S, Assal A, Shastri A, Gordon-Mitchell S, Pellagatti A, Boultwood J, Schinke C, Yu Y, Guha C, Rizzi J, Garrus J, Brown S, Wollenberg L, Hogeland G, Wright D, Munson M, Rodriguez M, Gross S, Chantry D, Zou Y, Platanias L, Burgess LE, Pradhan K, Steidl U, Verma A. Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia. Cancer Res. 2016 08 15; 76(16):4841-4849.

Mallick N, Anwar M, Asfer M, Mehdi SH, Rizvi MMA, Panda AK, Talegaonkar S, Ahmad FJ. Chondroitin sulfate-capped super-paramagnetic iron oxide nanoparticles as potential carriers of doxorubicin hydrochloride. Carbohydr Polym. 2016 Oct 20; 151:546-556.

Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DW, Qi L, Xu J, Hunziker W, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuiatse I, Tang JL, Wang H, He J, Yang J, Milan E, Cenci S, Ma WC, Wang ZQ, Davis RE, Yang L, Orlowski RZ. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell. 2016 05 09; 29(5):639-652.

Jurczyszyn A, Grzasko N, Gozzetti A, Czepiel J, Cerase A, Hungria V, Crusoe E, Silva Dias AL, Vij R, Fiala MA, Caers J, Rasche L, Nooka AK, Lonial S, Vesole DH, Philip S, Gangatharan S, Druzd-Sitek A, Walewski J, Corso A, Cocito F, Vekemans MC, Atilla E, Beksac M, Leleu X, Davila J, Badros A, Aneja E, Abildgaard N, Kastritis E, Fantl D, Schutz N, Pika T, Butrym A, Olszewska-Szopa M, Usnarska-Zubkiewicz L, Usmani SZ, Nahi H, Chim CS, Shustik C, Madry K, Lentzsch S, Swiderska A, Helbig G, Guzicka-Kazimierczak R, Lendvai N, Waage A, Andersen KT, Murakami H, Zweegman S, Castillo JJ. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol. 2016 06; 91(6):575-80.

Zhang X, Tang K, Wang H, Liu Y, Bao B, Fang Y, Zhang X, Lu W. Design, Synthesis, and Biological Evaluation of New Cathepsin B-Sensitive Camptothecin Nanoparticles Equipped with a Novel Multifuctional Linker. Bioconjug Chem. 2016 05 18; 27(5):1267-75.

Ord??ez PE, Sharma KK, Bystrom LM, Alas MA, Enriquez RG, Malag?n O, Jones DE, Guzman ML, Compadre CM. Dehydroleucodine, a Sesquiterpene Lactone from Gynoxys verrucosa, Demonstrates Cytotoxic Activity against Human Leukemia Cells. J Nat Prod. 2016 Apr 22; 79(4):691-6.

Wang H, Xie B, Kong Y, Tao Y, Yang G, Gao M, Xu H, Zhan F, Shi J, Zhang Y, Wu X. Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3. Oncotarget. 2016 Apr 05; 7(14):18638-50.

Birgeg?rd G, Henry D, Glaspy J, Chopra R, Thomsen LL, Auerbach M. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial. Pharmacotherapy. 2016 Apr; 36(4):402-14.

Spector ME, Chinn SB, Bellile E, Gallagher KK, Kang SY, Moyer JS, Prince ME, Wolf GT, Bradford CR, McHugh JB, Carey TE, Worden FP, Eisbruch A, Ibrahim M, Chepeha DB. Exploration for an Algorithm for Deintensification to Exclude the Retropharyngeal Site From Advanced Oropharyngeal Squamous Cell Carcinoma Treatment. JAMA Otolaryngol Head Neck Surg. 2016 Apr; 142(4):313-8.

Kovalchuk A, Rodriguez-Juarez R, Ilnytskyy Y, Byeon B, Shpyleva S, Melnyk S, Pogribny I, Kolb B, Kovalchuk O. Sex-specific effects of cytotoxic chemotherapy agents cyclophosphamide and mitomycin C on gene expression, oxidative DNA damage, and epigenetic alterations in the prefrontal cortex and hippocampus - an aging connection. Aging (Albany NY). 2016 04; 8(4):697-711.

Fadol AP, Banchs J, Hassan SA, Yeh ET, Fellman B. Withdrawal of Heart Failure Medications in Cancer Survivors With Chemotherapy-Induced Left Ventricular Dysfunction: A Pilot Study. J Card Fail. 2016 Jun; 22(6):481-2.

Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A, Toutouzas K, Leesar MA, Grines CL, Marmagkiolis K. Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue. Circulation. 2016 Mar 29; 133(13):1272-89.

Madadi NR, Ketkar A, Penthala NR, Bostian AC, Eoff RL, Crooks PA. Dioxol and dihydrodioxin analogs of 2- and 3-phenylacetonitriles as potent anti-cancer agents with nanomolar activity against a variety of human cancer cells. Bioorg Med Chem Lett. 2016 May 01; 26(9):2164-9.

Leach JC, Wang A, Ye K, Jin S. A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery. Int J Mol Sci. 2016 Mar 14; 17(3):380.

Kober KM, Dunn L, Mastick J, Cooper B, Langford D, Melisko M, Venook A, Chen LM, Wright F, Hammer M, Schmidt BL, Levine J, Miaskowski C, Aouizerat BE. Gene Expression Profiling of Evening Fatigue in Women Undergoing Chemotherapy for Breast Cancer. Biol Res Nurs. 2016 07; 18(4):370-85.

Dayer L, Dunn E, Pace A, Flowers S. Pharmacists' perceived knowledge of and confidence in dispensing oral antineoplastic agents. J Am Pharm Assoc (2003). 2016 Mar-Apr; 56(2):141-4.e2.

Swisher EM, Harrell MI, Norquist BM, Walsh T, Brady M, Lee M, Hershberg R, Kalli KR, Lankes H, Konnick EQ, Pritchard CC, Monk BJ, Chan JK, Burger R, Kaufmann SH, Birrer MJ. Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma. JAMA Oncol. 2016 Mar; 2(3):370-2.

Stine KC, Wahl EC, Liu L, Skinner RA, VanderSchilden J, Bunn RC, Montgomery CO, Aronson J, Becton DL, Nicholas RW, Swearingen CJ, Suva LJ, Lumpkin CK. Nutlin-3 treatment spares cisplatin-induced inhibition of bone healing while maintaining osteosarcoma toxicity. J Orthop Res. 2016 10; 34(10):1716-1724.

Gao M, Kong Y, Wang H, Xie B, Yang G, Gao L, Zhang Y, Zhan F, Dai B, Tao Y, Shi J. Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials. Tumour Biol. 2016 Aug; 37(8):11081-98.

Moudgil R, Yeh ET. Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond. Can J Cardiol. 2016 07; 32(7):863-870.e5.

van der Watt PJ, Chi A, Stelma T, Stowell C, Strydom E, Carden S, Angus L, Hadley K, Lang D, Wei W, Birrer MJ, Trent JO, Leaner VD. Targeting the Nuclear Import Receptor Kpn?1 as an Anticancer Therapeutic. Mol Cancer Ther. 2016 04; 15(4):560-73.

Shafirstein G, Battoo A, Harris K, Baumann H, Gollnick SO, Lindenmann J, Nwogu CE. Photodynamic Therapy of Non-Small Cell Lung Cancer. Narrative Review and Future Directions. Ann Am Thorac Soc. 2016 Feb; 13(2):265-75.

Khan S, Shukla S, Sinha S, Meeran SM. Epigenetic targets in cancer and aging: dietary and therapeutic interventions. Expert Opin Ther Targets. 2016 Jun; 20(6):689-703.

Kaushal GP, Shah SV. Autophagy in acute kidney injury. Kidney Int. 2016 Apr; 89(4):779-91.

Marachelian A, Desai A, Balis F, Katzenstein H, Qayed M, Armstrong M, Neville KA, Cohn SL, Bush M, Gunawan R, Lim AP, Smith MA, Smith LM. Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy. Cancer Chemother Pharmacol. 2016 Feb; 77(2):405-12.

Rajagopalan P, Alahmari KA, Elbessoumy AA, Balasubramaniam M, Suresh R, Shariff ME, Chandramoorthy HC. Biological evaluation of 2-arylidene-4, 7-dimethyl indan-1-one (FXY-1): a novel Akt inhibitor with potent activity in lung cancer. Cancer Chemother Pharmacol. 2016 Feb; 77(2):393-404.

Miaskowski C, Cooper BA, Aouizerat B, Melisko M, Chen LM, Dunn L, Hu X, Kober KM, Mastick J, Levine JD, Hammer M, Wright F, Harris J, Armes J, Furlong E, Fox P, Ream E, Maguire R, Kearney N. The symptom phenotype of oncology outpatients remains relatively stable from prior to through 1?week following chemotherapy. Eur J Cancer Care (Engl). 2017 May; 26(3).

Iliescu CA, Grines CL, Herrmann J, Yang EH, Cilingiroglu M, Charitakis K, Hakeem A, Toutouzas KP, Leesar MA, Marmagkiolis K. SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologia intervencionista). Catheter Cardiovasc Interv. 2016 Apr; 87(5):E202-23.

Puvvada SD, Li H, Rimsza LM, Bernstein SH, Fisher RI, LeBlanc M, Schmelz M, Glinsmann-Gibson B, Miller TP, Maddox AM, Friedberg JW, Smith SM, Persky DO. A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. Leuk Lymphoma. 2016 10; 57(10):2359-69.

Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Blad? J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016 Apr 09; 387(10027):1551-1560.

Sharp CN, Doll MA, Dupre TV, Shah PP, Subathra M, Siow D, Arteel GE, Megyesi J, Beverly LJ, Siskind LJ. Repeated administration of low-dose cisplatin in mice induces fibrosis. Am J Physiol Renal Physiol. 2016 Mar 15; 310(6):F560-8.

Hassen S, Ali AA, Kilaparty SP, Al-Anbaky QA, Majeed W, Boman BM, Fields JZ, Ali N. Interdependence of DNA mismatch repair proteins MLH1 and MSH2 in apoptosis in human colorectal carcinoma cell lines. Mol Cell Biochem. 2016 Jan; 412(1-2):297-305.

Moran-Jones K, Gloss BS, Murali R, Chang DK, Colvin EK, Jones MD, Yuen S, Howell VM, Brown LM, Wong CW, Spong SM, Scarlett CJ, Hacker NF, Ghosh S, Mok SC, Birrer MJ, Samimi G. Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. Oncotarget. 2015 Dec 29; 6(42):44551-62.

Iliescu C, Grines CL, Herrmann J, Yang EH, Cilingiroglu M, Charitakis K, Hakeem A, Toutouzas K, Leesar MA, Marmagkiolis K. SCAI expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (Endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencionista). Catheter Cardiovasc Interv. 2016 Apr; 87(5):895-9.

Zong H, Sen S, Zhang G, Mu C, Albayati ZF, Gorenstein DG, Liu X, Ferrari M, Crooks PA, Roboz GJ, Shen H, Guzman ML. In vivo targeting of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow niche. Leukemia. 2016 07; 30(7):1582-6.

Chang J, Wang Y, Shao L, Laberge RM, Demaria M, Campisi J, Janakiraman K, Sharpless NE, Ding S, Feng W, Luo Y, Wang X, Aykin-Burns N, Krager K, Ponnappan U, Hauer-Jensen M, Meng A, Zhou D. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med. 2016 Jan; 22(1):78-83.

Kelly KR, Espitia CM, Zhao W, Wendlandt E, Tricot G, Zhan F, Carew JS, Nawrocki ST. Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus. Oncotarget. 2015 Dec 01; 6(38):41275-89.

Franqui-Machin R, Wendlandt EB, Janz S, Zhan F, Tricot G. Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction? Oncotarget. 2015 Dec 01; 6(38):40496-506.

Weinhold N, Kirn D, Seckinger A, Hielscher T, Granzow M, Bertsch U, Egerer G, Salwender H, Blau IW, Weisel K, Hillengass J, Raab MS, Hose D, Goldschmidt H, Jauch A. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. Haematologica. 2016 Mar; 101(3):e116-9.

Wolfe AR, Debeb BG, Lacerda L, Larson R, Bambhroliya A, Huang X, Bertucci F, Finetti P, Birnbaum D, Van Laere S, Diagaradjan P, Ruffell B, Trenton NJ, Chu K, Hittelman W, Diehl M, Levental I, Ueno NT, Woodward WA. Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a. Breast Cancer Res Treat. 2015 Dec; 154(3):495-508.

Penthala NR, Ketkar A, Sekhar KR, Freeman ML, Eoff RL, Balusu R, Crooks PA. 1-Benzyl-2-methyl-3-indolylmethylene barbituric acid derivatives: Anti-cancer agents that target nucleophosmin 1 (NPM1). Bioorg Med Chem. 2015 Nov 15; 23(22):7226-33.

Lieber BA, Appelboom G, Taylor BE, Lowy FD, Bruce EM, Sonabend AM, Kellner C, Connolly ES, Bruce JN. Preoperative chemotherapy and corticosteroids: independent predictors of cranial surgical-site infections. J Neurosurg. 2016 07; 125(1):187-95.

Bam R, Khan S, Ling W, Randal SS, Li X, Barlogie B, Edmondson R, Yaccoby S. Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow. BMC Cancer. 2015 Nov 06; 15:864.

Ye H, Tanenbaum LM, Na YJ, Mantzavinou A, Fulci G, Del Carmen MG, Birrer MJ, Cima MJ. Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models. J Control Release. 2015 Dec 28; 220(Pt A):358-367.

Costantino C, Thomas GV, Ryan C, Coakley FV, Troxell ML. Metastatic renal cell carcinoma without evidence of a renal primary. Int Urol Nephrol. 2016 Jan; 48(1):73-7.

Corr BR, Finlay-Schultz J, Rosen RB, Qamar L, Post MD, Behbakht K, Spillman MA, Sartorius CA. Cytokeratin 5-Positive Cells Represent a Therapy Resistant subpopulation in Epithelial Ovarian Cancer. Int J Gynecol Cancer. 2015 Nov; 25(9):1565-73.

Firwana B, Sonbol MB, Diab M, Raza S, Hasan R, Yousef I, Zarzour A, Garipalli A, Doll D, Murad MH, Al-Kali A. Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison. Int J Cancer. 2016 Mar 15; 138(6):1545-53.

Hidayat AN, Aki-Yalcin E, Beksac M, Tian E, Usmani SZ, Ertan-Bolelli T, Yalcin I. Insight into human protease activated receptor-1 as anticancer target by molecular modelling. SAR QSAR Environ Res. 2015; 26(10):795-807.

Shiver MB, Mahmoud F, Gao L. Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma. N Engl J Med. 2015 Oct 15; 373(16):1580-2.

Khan S, Shukla S, Sinha S, Meeran SM. Centchroman altered the expressions of tumor-related genes through active chromatin modifications in mammary cancer. Mol Carcinog. 2016 Nov; 55(11):1747-1760.

van Rhee F, Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, Qin X, Qi M, Tromp B, Kurzrock R. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. Oncotarget. 2015 Oct 06; 6(30):30408-19.

Yang G, Gao M, Zhang Y, Kong Y, Gao L, Tao Y, Han Y, Wu H, Meng X, Xu H, Zhan F, Wu X, Shi J. Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I. Oncotarget. 2015 Sep 29; 6(29):26982-94.

Stine KC. Risk organ + LCH gets the one-two punch? Blood. 2015 Sep 17; 126(12):1399-400.

Epeldegui M, Lee JY, Mart?nez AC, Widney DP, Magpantay LI, Regidor D, Mitsuyasu R, Sparano JA, Ambinder RF, Mart?nez-Maza O. Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial). Clin Cancer Res. 2016 Jan 15; 22(2):328-36.

Dai L, Trillo-Tinoco J, Bai A, Chen Y, Bielawski J, Del Valle L, Smith CD, Ochoa AC, Qin Z, Parsons C. Ceramides promote apoptosis for virus-infected lymphoma cells through induction of ceramide synthases and viral lytic gene expression. Oncotarget. 2015 Sep 15; 6(27):24246-60.

Kober KM, Cooper BA, Paul SM, Dunn LB, Levine JD, Wright F, Hammer MJ, Mastick J, Venook A, Aouizerat BE, Miaskowski C. Subgroups of chemotherapy patients with distinct morning and evening fatigue trajectories. Support Care Cancer. 2016 Apr; 24(4):1473-85.

Madadi NR, Penthala NR, Howk K, Ketkar A, Eoff RL, Borrelli MJ, Crooks PA. Synthesis and biological evaluation of novel 4,5-disubstituted 2H-1,2,3-triazoles as cis-constrained analogues of combretastatin A-4. Eur J Med Chem. 2015 Oct 20; 103:123-32.

Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW, McCaffrey J, Newbold K, Allison R, Martins RG, Licitra LF, Shah MH, Bodenner D, Elisei R, Burmeister L, Funahashi Y, Ren M, O'Brien JP, Sherman SI. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):44-53.

Sethi P, Jyoti A, Swindell EP, Chan R, Langner UW, Feddock JM, Nagarajan R, O'Halloran TV, Upreti M. 3D tumor tissue analogs and their orthotopic implants for understanding tumor-targeting of microenvironment-responsive nanosized chemotherapy and radiation. Nanomedicine. 2015 Nov; 11(8):2013-23.

Klyuchnikov E, Bacher U, Kr?ger NM, Hari PN, Ahn KW, Carreras J, Bachanova V, Bashey A, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Hertzberg MS, Holmberg LA, Kharfan-Dabaja MA, Klein A, Ku GH, Laport GG, Lazarus HM, Miller AM, Mussetti A, Olsson RF, Slavin S, Usmani SZ, Vij R, Wood WA, Maloney DG, Sureda AM, Smith SM, Hamadani M. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2091-2099.

Huang J, Zhou Y, Thomas GS, Gu Z, Yang Y, Xu H, Tricot G, Zhan F. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma. Clin Cancer Res. 2015 Dec 15; 21(24):5532-42.

Elimova E, Shiozaki H, Slack RS, Chen HC, Wadhwa R, Sudo K, Charalampakis N, Hiremath A, Estrella JS, Matamoros A, Sagebiel T, Das P, Rogers JE, Garris JL, Blum MA, Badgwell B, Ajani JA. Early versus Delayed Therapy of Advanced Gastric Cancer Patients--Does It Make a Difference? Oncology. 2015; 89(4):215-20.

Frett B, Carlomagno F, Moccia ML, Brescia A, Federico G, De Falco V, Admire B, Chen Z, Qi W, Santoro M, Li HY. Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology. Angew Chem Int Ed Engl. 2015 Jul 20; 54(30):8717-21.

Agarwal A, Klair J, Patolia S, Meena NK. Intrapleural cisplatin for management of malignant pleural effusion in a patient with plasma cell leucaemia. BMJ Case Rep. 2015 Jun 29; 2015.

Casper C, Chaturvedi S, Munshi N, Wong R, Qi M, Schaffer M, Bandekar R, Hall B, van de Velde H, Vermeulen J, Reddy M, van Rhee F. Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease. Clin Cancer Res. 2015 Oct 01; 21(19):4294-304.

Lataifeh AR, Nusair A. Fatal pulmonary toxicity due to carfilzomib (Kyprolis?). J Oncol Pharm Pract. 2016 Oct; 22(5):720-4.

Alagpulinsa DA, Yaccoby S, Ayyadevara S, Shmookler Reis RJ. A peptide nucleic acid targeting nuclear RAD51 sensitizes multiple myeloma cells to melphalan treatment. Cancer Biol Ther. 2015; 16(6):976-86.

Penthala NR, Thakkar S, Crooks PA. Heteroaromatic analogs of the resveratrol analog DMU-212 as potent anti-cancer agents. Bioorg Med Chem Lett. 2015 Jul 15; 25(14):2763-7.

Herzog C, Marisiddaiah R, Haun RS, Kaushal GP. Basement membrane protein nidogen-1 is a target of meprin ? in cisplatin nephrotoxicity. Toxicol Lett. 2015 Jul 16; 236(2):110-6.

Zhan F, Zangari M, Qiu L. Drug resistance in hematologic malignancies: induction mechanisms, genetics, and therapeutics. Biomed Res Int. 2015; 2015:384575.

Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, Topliss D, Andresen C, O'Brien JP, Ren M, Funahashi Y, Allison R, Elisei R, Newbold K, Licitra LF, Sherman SI, Ball DW. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer. 2015 Aug 15; 121(16):2749-56.

Badgwell B, Blum M, Estrella J, Chiang YJ, Das P, Matamoros A, Fournier K, Mansfield P, Ajani J. Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy. J Am Coll Surg. 2015 Jul; 221(1):83-90.

Dighe SU, Khan S, Soni I, Jain P, Shukla S, Yadav R, Sen P, Meeran SM, Batra S. Synthesis of ?-Carboline-Based N-Heterocyclic Carbenes and Their Antiproliferative and Antimetastatic Activities against Human Breast Cancer Cells. J Med Chem. 2015 Apr 23; 58(8):3485-99.

Zhou Z, Badkas A, Stevenson M, Lee JY, Leung YK. Herceptin conjugated PLGA-PHis-PEG pH sensitive nanoparticles for targeted and controlled drug delivery. Int J Pharm. 2015 Jun 20; 487(1-2):81-90.

Franco FM, Jones DE, Harris PK, Han Z, Wildman SA, Jarvis CM, Janetka JW. Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets. Bioorg Med Chem. 2015 May 15; 23(10):2328-43.

Rodriguez A, Tatter SB. Neurosurgical management of brain metastases. Curr Probl Cancer. 2015 Mar-Apr; 39(2):89-98.

Schinke C, Giricz O, Li W, Shastri A, Gordon S, Barreyro L, Barreryo L, Bhagat T, Bhattacharyya S, Ramachandra N, Bartenstein M, Pellagatti A, Boultwood J, Wickrema A, Yu Y, Will B, Wei S, Steidl U, Verma A. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. Blood. 2015 May 14; 125(20):3144-52.

Zhang X, Kong Y, Zhang J, Su M, Zhou Y, Zang Y, Li J, Chen Y, Fang Y, Zhang X, Lu W. Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors. Eur J Med Chem. 2015 May 05; 95:127-35.

Saulnier Sholler GL, Bond JP, Bergendahl G, Dutta A, Dragon J, Neville K, Ferguson W, Roberts W, Eslin D, Kraveka J, Kaplan J, Mitchell D, Parikh N, Merchant M, Ashikaga T, Hanna G, Lescault PJ, Siniard A, Corneveaux J, Huentelman M, Trent J. Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma. Cancer Med. 2015 Jun; 4(6):871-86.

Hansson M, Gimsing P, Badros A, Niskanen TM, Nahi H, Offner F, Salomo M, Sonesson E, Mau-Sorensen M, Stenberg Y, Sundberg A, Teige I, Van Droogenbroeck J, Wichert S, Zangari M, Frendeus B, Korsgren M, Poelman M, Tricot G. A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2015 Jun 15; 21(12):2730-6.

Klair JS, Abraham RR, Jones J, Girotra M. A 'shock-ing' endoscopic finding on esophagogastroduodenoscopy. BMJ Case Rep. 2015 Feb 09; 2015.

Alford SE, Kothari A, Loeff FC, Eichhorn JM, Sakurikar N, Goselink HM, Saylors RL, Jedema I, Falkenburg JH, Chambers TC. BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells. Cancer Res. 2015 Apr 01; 75(7):1366-75.

Mathias TJ, Natarajan K, Shukla S, Doshi KA, Singh ZN, Ambudkar SV, Baer MR. The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations. Invest New Drugs. 2015 Apr; 33(2):300-9.

Yang Y, Shi J, Gu Z, Salama ME, Das S, Wendlandt E, Xu H, Huang J, Tao Y, Hao M, Franqui R, Levasseur D, Janz S, Tricot G, Zhan F. Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. Cancer Res. 2015 Feb 01; 75(3):594-604.

Oakley E, Wrazen B, Bellnier DA, Syed Y, Arshad H, Shafirstein G. A new finite element approach for near real-time simulation of light propagation in locally advanced head and neck tumors. Lasers Surg Med. 2015 Jan; 47(1):60-7.

Philchenkov AA, Zavelevich MP, Tryndyak VP, Kuiava LM, Blokhin DY, Miura K, Silvestri R, Pogribny IP. Antiproliferative and proapoptotic effects of a pyrrole containing arylthioindole in human Jurkat leukemia cell line and multidrug-resistant Jurkat/A4 cells. Cancer Biol Ther. 2015; 16(12):1820-9.

Penthala NR, Zong H, Ketkar A, Madadi NR, Janganati V, Eoff RL, Guzman ML, Crooks PA. Synthesis, anticancer activity and molecular docking studies on a series of heterocyclic trans-cyanocombretastatin analogues as antitubulin agents. Eur J Med Chem. 2015 Mar 06; 92:212-20.

Matulonis U, Vergote I, Backes F, Martin LP, McMeekin S, Birrer M, Campana F, Xu Y, Egile C, Ghamande S. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol. 2015 Feb; 136(2):246-53.

Schickling BM, England SK, Aykin-Burns N, Norian LA, Leslie KK, Frieden-Korovkina VP. BKCa channel inhibitor modulates the tumorigenic ability of hormone-independent breast cancer cells via the Wnt pathway. Oncol Rep. 2015 Feb; 33(2):533-8.